|
Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime
Time?
Apr 16, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Apr 16, 2026 What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Apr 16, 2026 Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Apr 16, 2026 Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation? Apr 16, 2026 Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603 Apr 16, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Apr 16, 2026 Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime Time? Apr 16, 2026 Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial Apr 16, 2026 Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Apr 16, 2026 What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Apr 16, 2026 Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium Apr 16, 2026 Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 |
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival Journal of Clinical Oncology, Volume 44, Issue 15, Page 1457-1464, May 2026. <br/> 2026-05-20T07:00:00Z Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial Journal of Clinical Oncology, Volume 44, Issue 15, Page 1416-1429, May 2026. <br/> 2026-05-20T07:00:00Z Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium Journal of Clinical Oncology, Volume 44, Issue 15, Page 1441-1456, May 2026. <br/> 2026-05-20T07:00:00Z Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Journal of Clinical Oncology, Volume 44, Issue 15, Page 1430-1440, May 2026. <br/> 2026-05-20T07:00:00Z Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603 Journal of Clinical Oncology, Volume 44, Issue 15, Page 1395-1400, May 2026. <br/> 2026-05-20T07:00:00Z Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Journal of Clinical Oncology, Volume 44, Issue 15, Page 1401-1415, May 2026. <br/> 2026-05-20T07:00:00Z Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation? Journal of Clinical Oncology, Volume 44, Issue 15, Page 1389-1394, May 2026. <br/> 2026-05-20T07:00:00Z Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Journal of Clinical Oncology, Volume 44, Issue 15, Page 1465-1467, May 2026. <br/> 2026-05-20T07:00:00Z Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Journal of Clinical Oncology, Volume 44, Issue 15, Page 1471-1472, May 2026. <br/> 2026-05-20T07:00:00Z Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Journal of Clinical Oncology, Volume 44, Issue 15, Page 1472-1473, May 2026. <br/> 2026-05-20T07:00:00Z Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Journal of Clinical Oncology, Volume 44, Issue 15, Page 1467-1469, May 2026. <br/> 2026-05-20T07:00:00Z Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Journal of Clinical Oncology, Volume 44, Issue 15, Page 1469-1471, May 2026. <br/> 2026-05-20T07:00:00Z What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Journal of Clinical Oncology, Volume 44, Issue 15, Page 1385-1388, May 2026. <br/> 2026-05-20T07:00:00Z Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime Time? Journal of Clinical Oncology, Volume 44, Issue 15, Page 1381-1384, May 2026. <br/> 2026-05-20T07:00:00Z The Liver We Share Journal of Clinical Oncology, Ahead of Print. <br/> Room 402 Journal of Clinical Oncology, Ahead of Print. <br/> |
Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage
Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood. 2026-05-18
Case 14-2026: A 50-Year-Old Woman with Vaginal Bleeding and Anemia A 50-year-old woman was admitted to the hospital because of vaginal bleeding and anemia. She had a history of fibroids and 1 month of progressive thrombocytopenia. A diagnosis was made. 2026-05-14
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease In this study involving persons with sickle cell disease, adenine base editing was used to target the promoters of HBG1 and HBG2 in autologous hematopoietic stem cells to increase fetal hemoglobin expression. 2026-05-07
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer In a phase 1–2 study of daraxonrasib, treatment-related adverse events of grade 3 or higher occurred in 30% of patients with previously treated RAS-mutated pancreatic cancer, and up to 35% of patients had an objective response. 2026-05-07
Reforming Payment for Clinician-Administered Drugs — Most-Favored-Nation Pricing in Medicare Part B The administration recently announced a new payment model to align some Medicare Part B drug payments with international pricing benchmarks. Various factors could affect the model’s scope and impact. 2026-05-07
Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer The authors describe the scientific foundations of a phase 1–2 study of daraxonrasib to treat metastatic pancreatic ductal adenocarcinomas. 2026-05-07
Reducing Bacterial Contamination of Blood Bags with a Double Knot In a study involving 180 blood bags, use of a double-knot closure rather than the usual single knot prevented bacterial contamination. This strategy may reduce the risk of blood-product contamination in resource-limited settings. 2026-05-07
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors Among patients with hemophilia A, the annualized rate of treated bleeding events with Mim8 was more than 96% lower than with on-demand therapy and more than 42% lower than with clotting factor prophylaxis. 2026-04-30
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer In a phase 1 trial of first-line zongertinib for HER2-mutated non–small-cell lung cancer, an objective response occurred in 76% of patients, with a median progression-free survival of 14.4 months. 2026-04-30
Barrett’s Esophagus This article summarizes the pathogenesis, diagnosis, and management of Barrett’s esophagus, a reflux-related condition with increased adenocarcinoma risk, highlighting endoscopic diagnosis, surveillance, and early curative therapy. 2026-04-30
Science behind the Study: A Second Factor VIIIa Mimetic for Hemophilia A The author describes the scientific foundations and implications of the results of a randomized, controlled trial of Mim8, a new mimetic of factor VIIIa, to treat hemophilia A. 2026-04-30
Membranoproliferative Glomerulonephritis Due to Cryoglobulinemia A 60-year-old woman with follicular lymphoma was evaluated for swelling and proteinuria that had persisted for 2 weeks. The patient’s plasma was clear at 37°C but turbid at 4°C. A kidney biopsy was performed. 2026-04-30
EGFR’s Poor Sibling The discovery that many lung cancers are driven by a single dominant constitutively activated “driver” oncogene represented a quantum leap in the therapy of lung cancer. Potent small molecules were developed that could turn off these genes, with dramatic clinical therapeutic efficacy. Before their discovery, cancer therapeutics were identified by... 2026-04-30
CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease In a patient with relapsed B-cell acute lymphoblastic leukemia and chronic GVHD, CD19 CAR T-cell therapy led to leukemia remission for 1 year and sustained resolution of active chronic GVHD without other immunosuppressive therapy. 2026-04-30
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. 2026-04-23
Asundexian for Secondary Stroke Prevention In a placebo-controlled trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. 2026-04-16
Ianalumab plus Eltrombopag in Immune Thrombocytopenia In a phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo. 2026-04-16
Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk Combined oral contraceptives and hormone-replacement therapy increase the risk of venous thromboembolism, although the absolute risk is low. Transdermal estradiol and micronized progesterone carry lower risk. 2026-04-16
Asundexian for Noncardioembolic Ischemic Stroke Despite the implementation of efficacious interventions for secondary prevention, patients with ischemic stroke or transient ischemic attack (TIA) remain at substantial residual risk for short- and long-term recurrent ischemic stroke and coronary events.1,2 Approximately three quarters of ischemic strokes or TIAs are noncardioembolic and may be attributable to... 2026-04-16
The Dismantling of Environmental Protections — A Grave Threat to America’s Health The Trump administration’s wide-ranging actions to dismantle U.S. environmental regulations will cause long-lasting health harms, disproportionately affecting low-income and other vulnerable groups. 2026-04-16
|
|
|
| |||
|
[Editorial] War in the Middle East: collateral damage
A month after the USA and Israel launched attacks on Iran, Iran and the USA agreed to a conditional 2-week ceasefire on April 8, 2026. However, strikes continued in Lebanon, and after peace talks failed to come to a resolution an end to the war is no closer at the time of writing and the situation in the region remains precarious. Furthermore, the effects of the US–Israel–Iran war are being felt not only in the region, but also globally, and the impact on health care worldwide is under-appreciated and likely long-lasting. Fri, 01 May 2026 00:00:00 -0700
[Comment] AKT-targeted triplet therapy in advanced breast cancer The advent of CDK4/6 inhibitors combined with endocrine therapy has substantially transformed the treatment approach for patients with HR+/HER2– metastatic breast cancer;1 however, acquired resistance inevitably develops, making the optimal sequencing of subsequent targeted therapies a substantial challenge. Aberrant activation of the PI3K/AKT/PTEN signalling axis is frequently identified as a key contributor to CDK4/6 inhibitor cross-resistance, providing a robust biological rationale for therapeutic intervention. Fri, 01 May 2026 00:00:00 -0700
[Comment] Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer Over the past decade, phase 3 trials have consistently demonstrated substantial progression-free survival and overall survival improvements with the addition of CDK4/6 inhibitors to endocrine therapy. The meta-analysis of Beshr and colleagues1 in The Lancet Oncology provides the most up-to-date analysis of data from phase 3 trials comparing CDK4/6 inhibitors plus endocrine therapy with endocrine therapy alone. By consolidating survival results, efficacy of this drug class in treatment of HR+/HER2– metastatic breast cancer is reaffirmed. Fri, 01 May 2026 00:00:00 -0700
[Comment] An old tool for new strategies in advanced prostate cancer Prostate-specific antigen (PSA) was discovered in 1960 and introduced as a biomarker for prostate cancer in 1987.1 Since then, PSA has been used for screening, detecting recurrence after prostatectomy or radiotherapy, and monitoring treatment response. Early work also demonstrated that PSA concentrations measured 6–9 months after initiating castration represent a major prognostic factor in metastatic castration-sensitive prostate cancer.2 Fri, 01 May 2026 00:00:00 -0700
[Comment] Refined outcome prediction in patients with extremity soft tissue sarcoma The rarity and heterogenous presentation of extremity soft tissue sarcomas complicates large-scale studies on diagnosis, disease monitoring, and outcome prediction. Histological subtype, grading, tumour size, location, resectability (with wide margins), administration of adjuvant or neoadjuvant radiotherapy, and chemotherapy all influence oncological outcomes, including local recurrence and risk of distant metastasis, as well as overall survival (figure).1 Given that the estimated prognosis of patients with soft tissue sarcoma guides decisions on individual treatment concepts, patient counselling, and follow-up strategies,2 the accurate prediction of oncological outcomes is important. Fri, 01 May 2026 00:00:00 -0700
[Comment] Ionising radiation and cancer: a UN review of the recent epidemiological evidence In 2019, the UN Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), whose mandate is to undertake scientific evaluations of the sources, effects, and risk of ionising radiation,1–3 convened a group of experts to review the latest epidemiological evidence on radiation and cancer risk. The updated report focuses on low-level radiation exposures; it has recently been approved and will be published in 2026.4 Fri, 01 May 2026 00:00:00 -0700
[Comment] Academic clinical cancer trials to improve patient outcomes Cancer clinical trials are conducted by both the commercial and non-commercial sectors. Whereas clinical trials conducted by the commercial sector aim for the marketing authorisation of new drugs, the primary characteristic of independent clinical trials conducted by the academic sector is the capacity to address a wide range of clinical research questions that are generally not addressed by the drug development industry. Crucial examples include the optimisation of surgical and radiation treatments, drug dose and treatment duration, multimodality combinations, sequence of treatments, head-to-head comparison of therapeutic strategies, better identification of patients who will or will not benefit, and addressing the needs of underserved patient populations. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] CAR T-cell therapy at first relapse in myeloma We congratulate Hermann Einsele and colleagues on their phase 3 CARTITUDE-4 trial, a landmark study poised to reshape the therapeutic landscape of relapsed myeloma. By finding a significant overall survival advantage with ciltacabtagene autoleucel (cilta-cel) compared with pomalidomide–bortezomib–dexamethasone or daratumumab–pomalidomide–dexamethasone in patients with lenalidomide-refractory myeloma with one to three previous lines of therapy, CARTITUDE-4 provides compelling evidence that earlier use of CAR T-cell therapy can alter disease trajectory. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] CAR T-cell therapy at first relapse in myeloma – Authors' reply We thank Jowon Laura Kim and S Vincent Rajkumar for their comments. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] How flaws in study design and lead-time bias could affect the interpretation of data We read with interest the systematic review by C Tang and colleagues1 and compliment the authors for their comprehensive primary analysis of six randomised clinical trials (RCTs) comparing metastasis-directed therapy (MDT) with standard of care (SOC) in oligometastatic prostate cancer. However, we identified several important design concerns and methodological limitations that could compromise the validity and interpretation of the findings. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] How flaws in study design and lead-time bias could affect the interpretation of data – Authors' reply We thank André Vis and Kim de Vries for their interest in our WOLVERINE study.1 We agree that, optimally, there will be well conducted phase III trials to inform the benefit of metastasis-directed therapy (MDT) for oligometastatic prostate cancer. However, these trials have yet to be reported, and in the interim, clinicians are left with an increasingly common clinical scenario that requires evidence-based direction. The highest-level data available are randomised phase 2 trials. However, heterogeneity exists between these trials given inherent differences and the timeframes over which they were run. Fri, 01 May 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: e218–30 Alger E, Regnault, A, Dueck AC, et al. A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR). Lancet Oncol 2026; 27: e218–30—The appendix of this Policy View has been corrected as of April 27, 2026. Fri, 01 May 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 461–69 Privé BM, Noordzij W, Muselaers CHJ, et al. [177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. Lancet Oncol 2026; 27: 461–69—In this Article, the title has been corrected to “[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study”. This correction has been made to the online version as of April 27, 2026. Fri, 01 May 2026 00:00:00 -0700
[News] Carcinogenicity of tris(chloropropyl) phosphate, butyraldehyde, and cumyl hydroperoxide In March, 2026, a Working Group of 12 scientists from nine countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of tris(chloropropyl) phosphate (TCPP), butyraldehyde, and cumyl hydroperoxide. Fri, 27 Mar 2026 08:00:04 +0000
[News] US oil blockade pushes Cuba's health system into crisis A US oil blockade causing several power blackouts in Cuba has led to tens of thousands of delayed surgeries while the health system tries to prioritise urgent care, including radiotherapy for 16 000 patients with cancer and chemotherapy for another 12 400 patients with cancer, say Cuban health authorities and the UN. Fri, 27 Mar 2026 23:30:01 +0000
[News] US cancer vaccines research at “tipping point” as NCI backs $200 million initiative The US National Cancer Institute (NCI) and the Foundation for the National Institutes of Health have launched a partnership to raise nearly US$200 million to fund clinical trials for cancer vaccines, including mRNA-based approaches for patients at high risk of tumour recurrence. Fri, 27 Mar 2026 23:30:01 +0000
[News] Senators demand explanation for US Preventive Services Task Force halt 19 US senators wrote to Health and Human Services Secretary Robert F Kennedy Jr on March 24, 2026, demanding he explain why the US Preventive Services Task Force (USPSTF)—the independent expert panel that has determined which cancer screenings and other preventive care Americans can access at no cost for four decades—has not met for a year. They called on Kennedy to submit an overdue, legally required annual USPSTF report to Congress, and to fill five vacancies among the 16 Task Force seats. Thu, 02 Apr 2026 22:30:01 +0000
[News] Canada's Yukon Territory publishes First Nations Cancer Strategy Canada's vast Yukon Territory in the country's northwest has published its first ever First Nations Cancer Strategy, aiming to improve cancer diagnosis, treatment, and care across the board for its First Nations people, who make up just less than 20% of the territory's population of around 48 000 people (2025 estimate). Some three-quarters of the population live in Whitehorse, the territory's capital near the southern border with the Province of British Colombia. Thu, 02 Apr 2026 22:30:03 +0000
[News] European Breast Cancer Conference 2026 Preliminary results of the ADARNAT pilot phase suggest that axillary radiotherapy (ART) without lymphadenectomy might safely replace axillary lymphadenectomy (ALND) in patients with limited node disease. Amparo Garcia-Tejedor (Hospital Universitari de Bellvitge, Gynecology, Hospitalet de Llobregat, Spain) presented results from the pilot phase of ADARNAT trial, an open-label, randomised, phase 3 multicentre trial across 23 Spanish hospitals. 272 patients with breast cancer (cT1–T4b, and cN0–cN1) treated with neoadjuvant therapy and 1–2 positive sentinel lymph nodes at surgery were randomly assigned to receive ART or ALND. Thu, 02 Apr 2026 22:30:01 +0000
[News] UK MHRA–NICE pathway to create faster regulatory approval A new aligned pathway has been established by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) to facilitate earlier patient access to medicines, according to recently published guidance. Fri, 10 Apr 2026 22:30:01 +0000
[News] Trump's 2027 budget calls for further cuts to health research Medical groups are preparing to lobby Congress over health cuts proposed in the 2027 budget by the US Trump administration in the hope that lawmakers will ensure funding when spending plans are negotiated in the coming months. Thu, 16 Apr 2026 22:30:01 +0000
[Perspectives] CHEMO MAN—or how we used to remember It caught my attention one Sunday as I did inpatient rounds. Pinned to a corkboard, fading slightly at the edges, the drawing looked almost childish at first glance. A smiling stick figure labelled CHEMO MAN, organs sketched in block letters and arrows pointing outwards with names of drugs and toxicities carefully written in pen. Doxorubicin for the heart. Bleomycin for the lungs. Cisplatin for the kidneys. Methotrexate for the liver. Vincristine for the nerves. A mnemonic rendered as a body and, unintentionally, a theory of learning. Fri, 01 May 2026 00:00:00 -0700
[Perspectives] Turning breast cancer into art with Cancer Research UK On Jan 20–25, 2026, the Business Design Centre in London, UK, hosted the annual London Art Fair, which for the first time had Cancer Research UK (London, UK) as its official charity partner. Cancer Research UK, used their platform at the London Art Fair to showcase two artists whose lives have been affected by breast cancer. Tucked away in a quiet upstairs corner of the fair, slightly aside from the bustling central area, Cancer Research UK's relatively small exhibition displayed the works of Dr Helen Anahita Wilson and Carole Ellis, two revolutionary and incredibly talented artists and survivors of breast cancer. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating total and diagnosed global cancer incidence and stage distribution from 1990 to 2050: a simulation-based analysis of 17 cancers These findings highlight the substantial and growing burden of cancers, especially in low-income and middle-income countries, where many people who develop cancer die undiagnosed. Accounting for demographic and epidemiological trends as well as health system factors, our modelling framework enables evaluation of targeted interventions to strengthen the cancer workforce and improve diagnostic pathways across diverse geographical and socioeconomic settings. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers Disparities in global cancer survival are large and are expected to persist on current trends without transformative policy action. Our modelling framework provides comprehensive, country-level projections of survival and mortality for multiple cancers, accounting for demographic and epidemiological trends, as well as health system barriers and workforce constraints. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating the impact of scaling up workforce personnel on global cancer mortality from 2030 to 2050: a simulation-based analysis of 17 cancers and 18 personnel types Investments to strengthen the cancer workforce will be essential to reduce global cancer mortality and improve timely diagnosis and survival. Strategic scale-up of personnel, particularly in diagnostics, alongside innovative strategies such as digital health solutions and role delegation, could result in substantial improvements in cancer outcomes. Policy makers should prioritise data-driven workforce planning as a crucial component of comprehensive cancer control strategies. Fri, 01 May 2026 00:00:00 -0700
[Articles] Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial The combination of fulvestrant, ipatasertib, and palbociclib showed preliminary signs of clinical activity and showed expected adverse events in heavily pretreated patients with HR+/HER2– metastatic breast cancer, warranting further evaluation in those with CDK4/6 inhibitor-refractory disease. Fri, 01 May 2026 00:00:00 -0700
[Articles] CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials CDK4/6 inhibitors plus endocrine therapy significantly improved survival in hormone receptor-positive, HER2-negative advanced breast cancer. Benefits in progression-free survival and overall survival were consistent across major clinical subgroups. Although all agents improved progression-free survival, only ribociclib and abemaciclib showed statistically significant overall survival benefits, whereas palbociclib did not, and data for dalpiciclib remain immature. Further head-to-head comparisons and assessments of toxicity profiles, as well as patient-reported outcomes, are needed. Fri, 01 May 2026 00:00:00 -0700
[Articles] Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials Performing SLNB or cALND solely to determine eligibility for CDK4/6 inhibition requires very high number needed to diagnose and treat, adds substantial morbidity, and is costly, with only marginal overall survival benefit. Fri, 01 May 2026 00:00:00 -0700
[Articles] Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial Along with the known survival benefits, the clinically meaningful delays in pain progression and time to deterioration of overall wellbeing support consideration of darolutamide plus ADT as a standard-of-care treatment option in patients with mHSPC. Thu, 09 Apr 2026 22:30:01 +0000
[Articles] On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials Metastatic volume or nodal status influence survival rates associated with on-treatment serum PSA categories, including for undetectable PSA. Radiological features and serum PSA could be combined to better predict survival. PSA at 24 weeks showed strongest associations with overall survival, although a PSA concentration of 0·2 ng/mL or less at any timepoint predicted favourable outcome. These findings could inform prognosis and warrant evaluation for treatment selection in clinical trials. Fri, 01 May 2026 00:00:00 -0700
[Articles] Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study BayeSarc is a continuously updatable, accurate, and precise prognostic tool for soft tissue sarcomas in the extremities. It reduces uncertainty, adapts to temporal changes, and refines variable weights. Its incorporation into the Sarculator app enables immediate clinical use, with potential to improve patient counselling, guide treatment decisions, and refine trial design. More broadly, the BSL framework provides an innovative and generalisable approach to prognostication in rare cancers, moving beyond the traditional two-step development–validation paradigm, enabling more efficient use of patient data. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium Oligometastatic cancer is characterised by a low volume of metastases to a small number of anatomical sites. However, evaluating the impact of metastases-directed therapies (MDTs) on overall survival or quality of life is often challenging. Current clinical trials use a wide range of primary endpoints that might not be validated or suited to MDT. To address this issue, we did a systematic review of international trial registries, alongside a Delphi consensus process involving 30 experts and five patient representatives. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment This multisociety, multidisciplinary consensus—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—was developed to standardise the assessment of ablation margins in liver tumour thermal ablation. A modified Delphi process, consisting of two online surveys and a hybrid (online and in-person meeting in Innsbruk) consensus meeting of 72 experts from North America, South America, Europe, and Asia. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards Thermal ablation offers a safer, less invasive, and more cost-effective curative-intent treatment for selected patients with primary and metastatic liver tumours than surgery; when done with appropriate technique, ablation can deliver similar oncological outcomes. However, effectiveness in routine practice varies because structured training, planning, and procedural governance remain scarce. These international multidisciplinary, multi-society guidelines—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—define key domains contributing to procedural difficulty and practice variation in liver tumour thermal ablation. Fri, 01 May 2026 00:00:00 -0700
|
Correction to “Health care discrimination and self‐reported health in transgender, gender nonconforming, and nonbinary individuals with cancer”
Fri, 22 May 2026 23:40:35 -0700 Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact Cy‐JAK/STAT pathway mutations are uncommon in AML, but each mutation has distinct biologic and clinical characteristics. The worse survival observed in patients with JAK2‐mutated AML largely appeared to be driven by the co‐occurrence of high‐risk characteristics. Blast‐phase MPN was associated with a dismal prognosis. Fri, 22 May 2026 23:06:00 -0700 Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high‐risk prostate cancer: A predictive biomarker analysis Low testosterone at diagnosis does not appear to predict a reduced mortality risk when adding docetaxel to RT and ADT in otherwise healthy patients with nonmetastatic high‐risk PC, whereas normal testosterone does, which provides evidence to support testosterone group as a predictive biomarker. Fri, 22 May 2026 22:12:52 -0700 Understudied and overlooked: Addressing sexual quality of life for couples facing metastatic breast cancer Wed, 20 May 2026 23:15:57 -0700 Bridging the gap to improve skin cancer prevention practices in childhood cancer survivors Wed, 20 May 2026 22:50:16 -0700 Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma Wed, 20 May 2026 04:00:11 -0700 Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial These findings support the feasibility of incorporating venetoclax into a fludarabine and melphalan conditioning regimen in older adults with AML/MDS. Notably, the low rates of GVHD and relapse associated with this venetoclax‐based conditioning regimen support further study of this platform [ClinicalTrials.gov Identifier: NCT05084027]. Wed, 20 May 2026 03:48:23 -0700 Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM‐3 Wed, 20 May 2026 03:25:25 -0700 Issue Information Wed, 20 May 2026 03:01:15 -0700 |
Genomic Therapy Matching in Rare and Refractory Cancers
This cohort study assesses whether a tiered, evidence-based framework for matching genomic biomarkers to therapies is associated with differential overall survival in patients with advanced solid tumors. Diagnostic Performance of Anti–Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma This multicenter, prospective cohort study assesses the diagnostic performance of anti–Epstein-Barr virus (EBV) BNLF2b in outpatients presenting with suspected nasopharyngeal carcinoma, and compares it with the anti-EBV capsid antigen, anti-EBV early antigen, and anti-EBV nuclear antigen 1 assays. Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial This randomized clinical trial evaluates the efficacy and safety of bireociclib plus fulvestrant in hormone receptor–positive, Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer This cohort study validates a novel parsimonious, interpretable, and generalizable model for predicting incident pancreatic ductal adenocarcinoma. Combination of Radiotherapy and Immunotherapy in Advanced Non–Small Cell Lung Cancer This cohort study compares real-world overall survival between sequential and concurrent radiotherapy and immunotherapy among patients with newly diagnosed advanced non–small cell lung cancer. Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial This secondary analysis of a randomized clinical trial explores treatment outcome preferences among older adults with advanced cancer, specifically whether survival or quality of life matters most to the patient. Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis. Survival Without Adjuvant Therapy for Low-Risk Endometrial Cancer With Isolated Tumor Cells This cohort study assesses overall survival without adjuvant therapy in patients with uterine factor–based low-risk endometrial cancer who had isolated tumor cells present in regional lymph nodes. Extensive Oral Ulcerations After Stem Cell Transplant A 69-year-old male patient presented with worsening new-onset oral ulcerations and pain. He had myelodysplastic syndrome and underwent an allogeneic hematopoietic stem cell transplant 18 months prior. What is your diagnosis? Implementing Cancer Medicines on the WHO Model Lists of Essential Medicines Into National Systems This Viewpoint discusses national systems implementation of cancer medicines included in the WHO Model Lists of Essential Medicines. Obesity Control’s Underestimated Potential for Cancer Prevention This Viewpoint discusses obesity prevention and control as an underestimated and underutilized strategy in the prevention of numerous cancers. Insurance Barriers to Next-Generation Sequencing Testing in Lung Cancer—When Policy Delays Care This Viewpoint discusses insurance barriers to next-generation sequencing (NGS) testing for patients with non–small cell lung cancer and proposes policy solutions to address these barriers. The Next Frontier for Transparency in Cancer Randomized Clinical Trials—Data and Safety Monitoring Boards This Viewpoint discusses increasing the transparency in cancer randomized clinical trials through the use of data and safety monitoring boards. JAMA Oncology—TheYear in Review, 2025 Performance of Stereotactic Radiotherapy vs Hippocampal-Avoidance Whole Brain Radiation Delivering Precision Oncology at Scale—Infrastructure, Evidence, and the Path Forward Person-Centered Care in Geriatric Oncology—Understanding What Matters Most Local Consolidative Therapy in Lung Cancer This The Good Cancer, the Barely Cancer, and the Incurable Cancer This essay discusses the author’s reflection on his third cancer diagnosis and how he has lived with cancer throughout his life. The Vocabulary of Survival Possible Biases May Have Limited Study on Ultraprocessed Food Intake Possible Biases May Have Limited Study on Ultraprocessed Food Intake—Reply Error in Tables 2 and 3 JAMA Oncology JAMA Oncology Peer Reviewers in 2025 |
|
|
| |||
|
[Editorial] Mental health at the heart of haematology
May is a time to elevate mental health awareness. In the USA, May is designated as Mental Health Awareness Month; Europe marks Mental Health Week (May 4–8); and the UK observes Mental Health Awareness Week (May 11–17). These events invite a renewed collective focus on connection, resilience, and hope for the more than one billion people worldwide who live with mental health conditions, placing a substantial burden on individuals and health systems. Yet, our understanding of mental health within the fields of haematology and haematological oncology remains limited. Fri, 01 May 2026 00:00:00 -0700
[Comment] Two decades of phase 1 and 2 trials in relapsed or refractory diffuse large B-cell lymphoma Since the year 2000, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have authorised many novel cancer therapies based on phase 1–2 single-arm trials.1,2 Most of these were granted as conditional marketing authorisations (EMA) or Accelerated Approvals (FDA), which aim to provide early access to promising therapies in diseases with high unmet medical need. Acknowledging that single-arm trials can show biological activity but cannot reliably establish whether an experimental treatment is better than the current standard, these approvals are contingent on demonstration of clinical benefit in subsequent confirmatory randomised trials. Fri, 01 May 2026 00:00:00 -0700
[In Focus] Leveraging TikToks in clinical practice TikToks (short vertical videos) are increasingly infiltrating our lives, as well as those of our patients. In mid-2020, TikTok was one of the fastest growing social media platforms, with over half a billion active users and with TikToks also routinely viewed on other social media platforms or shared directly by friends and family. Armed with this knowledge, in my role as Director of the donor recruitment organisation Stem Cell Club, I led the development of a library of TikToks to engage young adults to stem-cell donation. Fri, 01 May 2026 00:00:00 -0700
[In Focus] From enrolment to authorship: racial and global disparities in phase 3 multiple myeloma clinical trials Clinical trials in multiple myeloma continue to fail populations most affected by the disease, with Black individuals remaining profoundly underrepresented in the studies that define contemporary treatment standards. Multiple myeloma is the second most common haematological malignancy, and the incidence, prevalence, and disability-adjusted life years attributable to the disease have increased over time, with mortality rates remaining high. Despite this burden, the therapeutic landscape of multiple myeloma has been transformed by the development of novel agents evaluated in clinical trials, resulting in substantial improvements in survival and meaningful gains in quality of life. Fri, 01 May 2026 00:00:00 -0700
[Articles] Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial Very early PET-guided intensification with BrECADD yields high activity in advanced-stage classic Hodgkin lymphoma while sparing most patients intensive chemotherapy. Fri, 01 May 2026 00:00:00 -0700
[Articles] Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial Pirtobrutinib was highly active and well tolerated, regardless of previous exposure to covalent BTK inhibitors, and might be a promising new therapeutic option for patients with relapsed or refractory Waldenström macroglobulinaemia, particularly in those previously exposed to covalent BTK inhibitors, for whom durable and effective treatments are needed. Fri, 01 May 2026 00:00:00 -0700
[Articles] Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis Since the year 2000, early-phase trials in relapsed or refractory diffuse large B-cell lymphoma have shown more than a doubling of response rates, driven primarily by cellular and bispecific antibody therapies, while maintaining low treatment-related mortality. These results provide risk-benefit trends in early-phase trials and define contemporary benchmarks for clinicians, investigators and regulators. Fri, 01 May 2026 00:00:00 -0700
[Articles] Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial In this setting, Peg-IFN combined with nilotinib induced higher initial rates of MR4·5 compared to TKI monotherapy, despite additional side effects. The onset of psychiatric events might promote immediate cease of Peg-IFN and psychiatrist advice Whether this early molecular response translates into sustained treatment-free survival should be studied in a randomised trial sufficiently powered for this outcome. Fri, 01 May 2026 00:00:00 -0700
[Review] Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies The development of novel T-cell redirecting immune therapies—including immune checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor T cells, and virus-specific T cells—represents a major advancement in the treatment of haematological malignancies. Although such therapies have strong evidence for efficacy in the treatment of B-cell neoplasms, several unique challenges are encountered when using these therapies for the treatment of T-cell malignancies. In this Review, we discuss the application of T-cell modulating immune therapies in T-cell neoplasms, with a focus on the complicated bidirectional interactions between malignant and bystander T cells in disease pathogenesis, and the resultant challenges affecting the design and deliverability of T-cell modulating therapies in this cohort. Fri, 03 Apr 2026 22:30:00 +0000
[Review] Guidelines for the management of acute porphyria: recommendations from the International Porphyria Network Autosomal dominant acute porphyrias are rare inherited disorders of haem biosynthesis characterised by accumulation of potentially neurotoxic porphyrin precursors and attacks of severe abdominal pain with autonomic and neuropsychiatric features. Disease severity ranges from asymptomatic individuals to those with recurrent, life-threatening attacks. The International Porphyria Network invited 34 acute porphyria specialists from 17 countries to form an expert panel. The invited group included clinicians from diverse specialities (ie, internal medicine, haematology, endocrinology, gastroenterology, hepatology, neurology, and biochemistry), together with laboratory scientists and patient representatives. Fri, 01 May 2026 00:00:00 -0700
[Clinical Picture] An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass A 69-year-old woman was referred to our department after monoclonal gammopathy was detected during routine testing. Her medical history included dyslipidaemia, hypothyroidism, and right hip replacement due to congenital dysplasia. Physical examination, complete blood count, and serum biochemical tests were unremarkable. Immunofixation revealed monoclonal IgGλ (total IgG 1060 mg/dL), with a normal free light chain (FLC) ratio. Urine immunofixation was negative. A bone marrow biopsy showed 12% clonal plasma cell infiltration, consistent with smouldering multiple myeloma (SMM) pending whole-body, low-dose CT (WBLD–CT). Thu, 02 Apr 2026 22:30:01 +0000
[Clinical Picture] Protein-losing enteropathy in marginal zone lymphoma: tissue is the issue A 67-year-old woman was diagnosed with nodal marginal zone lymphoma with IgMκ paraproteinaemia, circulating monoclonal B cells, multifocal lymph node involvement (MYD88WT), and splenomegaly. Rituximab monotherapy yielded partial metabolic remission on PET–CT and an IgM concentration decrease from 15·4 g/L to 12·4 g/L (normal range: 0·4–2·3 g/L). However, the patient reported severe progressive diarrhoea (up to 50 times per day). A 13 kg weight loss resulted in total parenteral nutrition dependence. Fri, 01 May 2026 00:00:00 -0700
|
Old drug, new parasite: targeting leukemia with antifungals
Volume 147, Issue 21 May 21 2026 Refractoriness in TTP: challenges and solutions Volume 147, Issue 21 May 21 2026 TCF3::HLF drives fatal B-ALL thriving on inflammation Volume 147, Issue 21 May 21 2026 Orca-T as a force multiplier for HCT immune tolerance Volume 147, Issue 21 May 21 2026 Can we target CTCL clonal evolution and improve outcomes? Volume 147, Issue 21 May 21 2026 No need to wait: treat iron deficiency in the hospital Volume 147, Issue 21 May 21 2026 No TFPI? APC to the rescue! Volume 147, Issue 21 May 21 2026 Blocking ANGPT2: from VW disease to vascular normalization Volume 147, Issue 21 May 21 2026 A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia Although targeting mitochondrial oxidative phosphorylation (OXPHOS) can overcome treatment resistance in preclinical acute myeloid leukemia (AML) models, currently available OXPHOS inhibitors have shown limited potency in clinical trials. In a Plenary Paper, Himonas et al report a nutrient-sensing drug-repurposing screen identifying itraconazole, a US Food and Drug Administration–approved antifungal agent, as an inhibitor of mitochondrial metabolism in AML. Itraconazole targets therapy-resistant AML cells, particularly when combined with cytarabine, through inhibition of electron transport chain complex I activity. As azole antifungals are routinely used for fungal prophylaxis in patients with AML, this approach should be easily amenable to clinical testing.
Volume 147, Issue 21 May 21 2026 Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps While daratumumab-based regimens have transformed therapy for light-chain (AL) amyloidosis, a gap has emerged between current outcomes and prognostic models derived from patients treated with earlier therapies. In a Special Report, Chakraborty et al review prognostic factors and progression biomarkers in AL amyloidosis, noting that some traditional baseline markers are losing predictive value. In contrast, newer approaches such as minimal residual disease assessment by free light-chain mass spectrometry and advanced cardiac imaging parameters may offer greater prognostic utility. Further validation and refinement of prognostic models are needed to identify high-risk patients who may benefit from additional therapy.
Volume 147, Issue 21 May 21 2026 Revisiting clinical response and refractoriness in immune thrombotic thrombocytopenic purpura Refractory thrombotic thrombocytopenic purpura (TTP) has historically been reported to occur in 10% to 40% of patients with TTP, but these estimates do not reflect the incorporation of caplacizumab into frontline therapy. In a multicenter registry study of 204 patients, Kühne et al demonstrate that refractoriness during caplacizumab treatment in immune TTP is uncommon and, when observed, is typically associated with confounding clinical factors. These findings underscore the importance of careful clinical reassessment and evaluation for alternative etiologies in patients with delayed platelet recovery, rather than attributing such cases to true treatment resistance.
Volume 147, Issue 21 May 21 2026 Self-reinforcing IL-1β signaling accelerates the development and recurrence of TCF3::HLF-positive B-ALL TCF3::HLF-positive B-cell acute lymphoblastic leukemia (B-ALL) is a rare, highly fatal leukemia characterized by poor outcomes and severe osteolysis. Suzuki et al leveraged a newly developed mouse model of highly aggressive TCF3::HLF-driven B-ALL to uncover a previously unrecognized dependency on a proinflammatory interleukin-1β (IL-1β)–RANKL axis. They show that IL-1β and RANKL promote leukemia progression and osteoclast activation, whereas IL-1β blockade suppresses leukemic proliferation and mitigates bone destruction. This study provides important mechanistic insight into this rare leukemia subtype and identifies actionable therapeutic vulnerabilities.
Volume 147, Issue 21 May 21 2026 Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy The Orca-T allogeneic hematopoietic stem cell transplant product, which delivers purified CD4+CD25+CD127− regulatory T cells with hematopoietic stem cells followed by delayed infusion of conventional T cells, improves chronic graft-versus-host disease (GVHD)–free survival in clinical trials, but its mechanism remains unclear. Bader et al identified a transient regulatory-like CD4+ conventional T-cell population that emerges early after Orca-T therapy and correlates with tolerance-associated immune reconstitution after both Orca-T and standard allogeneic transplantation. These findings suggest that the timing and composition of transferred T cells can imprint durable immune states and may inform comparisons with other GVHD prevention strategies, including posttransplant cyclophosphamide.
Volume 147, Issue 21 May 21 2026 Multiomic study of cutaneous T-cell lymphoma reveals single-cell clonal evolution in progression and therapy resistance Cutaneous T-cell lymphoma remains difficult to treat because of therapy resistance. Dorando et al analyzed longitudinal multiomic data from 34 patients at progression, identifying recurrent clonal genomic alterations and key oncogenic and immune regulatory pathways. Clonal evolution in resistant disease is enriched for epigenetic modifiers, immune signaling, and checkpoint pathways, highlighting mechanisms of immune evasion and supporting integrated omics to predict refractoriness and guide therapy.
Volume 147, Issue 21 May 21 2026 A retrospective, real-world study of IV iron use to treat iron deficiency anemia during acute infection Iron deficiency anemia is common in hospitalized patients with infection, but IV iron is often withheld because of concerns that it may worsen outcomes. In a propensity-matched retrospective study described in this month’s CME article, Sohail et al show that IV iron given during acute infection with iron deficiency anemia is associated with improved 14-day and 90-day survival as well as hemoglobin recovery. Although this report has the limitations of a retrospective study, these findings challenge current practice and support randomized trials that include patients with infection.
Volume 147, Issue 21 May 21 2026 Defective cerebrovascular development in mice lacking TFPI is restored by activated protein C Volume 147, Issue 21 May 21 2026 Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2: relevance for gut angiodysplasia In patients with von Willebrand disease (VWD), recurrent gastrointestinal bleeding is associated with the presence of angiodysplasia. Constantinescu-Bercu et al show that endothelial von Willebrand factor regulates multiple steps of angiogenesis, including sprouting and lumen formation controlling the storage and expression of angiopoietin-2. Blocking angiopoietin-2 normalizes defective angiogenesis in VWD endothelial colony-forming cells, providing a rationale for therapeutic angiopoietin-2 inhibition in patients with VWD-associated gastrointestinal bleeding and angiodysplasia.
Volume 147, Issue 21 May 21 2026 Thymoma-associated aplastic anemia with concurrent Good syndrome Volume 147, Issue 21 May 21 2026 Funk CR, Wang S, Chen KZ, et al. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood. 2022;139(4):523-537. Volume 147, Issue 21 May 21 2026 Shanmuganathan N, Yeung DT, Wadham C, et al. Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. Blood. 2025;146(23):2821-2832. Volume 147, Issue 21 May 21 2026 IV iron for IDA during acute infection Volume 147, Issue 21 May 21 2026 |
CAR T‐Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study
Sun, 17 May 2026 18:38:28 -0700 Predictors of Relapse and Post‐Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome‐Negative B‐ALL Sun, 17 May 2026 18:35:09 -0700 Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management Fri, 15 May 2026 05:16:46 -0700 Chronic Anemia Patients Demonstrate Diffuse Demyelination Thu, 14 May 2026 20:46:50 -0700 Performance Evaluation of a Novel Non‐Invasive Monitoring Device for At‐Home Neutropenia Detection in a Multicenter Cancer Cohort Thu, 14 May 2026 06:04:44 -0700 Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma Thu, 14 May 2026 04:45:26 -0700 Accuracy of Diagnosis in Myeloproliferative Neoplasms With Splanchnic Vein Thrombosis (MPN‐SVT) Thu, 14 May 2026 01:34:28 -0700 Pre‐Transplant MRD Negativity and Age Under 40 Predict Superior Long‐Term Survival in Relapsed/Refractory B‐ALL After CAR‐T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6‐Year Follow‐Up Wed, 13 May 2026 22:22:43 -0700 Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant Wed, 13 May 2026 18:21:00 -0700 RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma Tue, 12 May 2026 22:35:13 -0700 Thrombotic Microangiopathy, Cryoglobulinemia, and Acute Kidney Injury in Patients With Monoclonal Gammopathy: A Case Series Tue, 12 May 2026 22:25:15 -0700 The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation Tue, 12 May 2026 05:33:33 -0700 Striking Bone Marrow Plasmacytosis Resulting From Visceral Leishmaniasis Tue, 12 May 2026 05:22:04 -0700 Management of Iron Overload in Infants and Toddlers With Diamond–Blackfan Anemia Syndrome: A French–Italian Study Mon, 11 May 2026 00:04:14 -0700 Real‐World Efficacy and Safety of Glofitamab‐Based Salvage Therapy in Chinese Patients With Relapsed or Refractory Aggressive B‐Cell Lymphomas Sun, 10 May 2026 23:46:12 -0700 Real‐World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease Fri, 08 May 2026 20:09:59 -0700 Hemophagocytic Lymphohistiocytosis After CAR T‐Cell Therapy: A Systematic Review and Meta‐Analysis Tue, 05 May 2026 19:57:16 -0700 Rare and Deadly Complication of Disseminated Toxoplasma gondii Infection After Allogeneic Hematopoietic Stem Cell Transplantation: Hemophagocytic Lymphohistiocytosis Tue, 05 May 2026 00:23:11 -0700 Late Onset Telomere Biology Disorder Presenting With Pancytopenia, Immune Dysregulation, Interstitial Lung Disease and Alopecia Tue, 05 May 2026 00:23:11 -0700 Marked Platelet Clumping and Giant Platelets due to GP Ib/IX Autoantibodies Tue, 05 May 2026 00:23:11 -0700 Cryohydrocytosis: When Cold Breaks the Membrane Tue, 05 May 2026 00:23:11 -0700 |
|
|
| |||
|
Boosting “Treg-ulation”: a good way to treat chronic GVHD? May 12 2026 - Volume 10, Issue 9 Hemoglobinopathy diagnostics: the HELIOS Action survey May 12 2026 - Volume 10, Issue 9 Halofuginone vs the elevated hepcidin hurdle May 12 2026 - Volume 10, Issue 9 Ravulizumab in pregnancy: the case for cautious optimism May 12 2026 - Volume 10, Issue 9 Timing is everything: age-dependent cancer risk in RUNX1-FPD May 12 2026 - Volume 10, Issue 9 LMWH dose reduction in CAT: not so fast! May 12 2026 - Volume 10, Issue 9 Adherence to ITP guidelines and adequate immunotherapy May 12 2026 - Volume 10, Issue 9 Interpreting next-generation immunosequencing results in children and young adults with acute lymphoblastic leukemia May 12 2026 - Volume 10, Issue 9 Persistence of PET scan positivity after chemoimmunotherapy for DLBCL May 12 2026 - Volume 10, Issue 9 Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease May 12 2026 - Volume 10, Issue 9 Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma May 12 2026 - Volume 10, Issue 9 Characteristics associated with clinical response to pomalidomide in hereditary hemorrhagic telangiectasia May 12 2026 - Volume 10, Issue 9 A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase 1/2 trials May 12 2026 - Volume 10, Issue 9 Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation May 12 2026 - Volume 10, Issue 9 Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries May 12 2026 - Volume 10, Issue 9 Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy May 12 2026 - Volume 10, Issue 9 Hematologic malignancies in pediatric patients with RUNX1-familial platelet disorder with associated myeloid malignancy May 12 2026 - Volume 10, Issue 9 Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias May 12 2026 - Volume 10, Issue 9 Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma May 12 2026 - Volume 10, Issue 9 VLA-4 agonist promotes engraftment and immune reconstitution of allogeneic hematopoietic stem cells May 12 2026 - Volume 10, Issue 9 Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma May 12 2026 - Volume 10, Issue 9 Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT May 12 2026 - Volume 10, Issue 9 Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study May 12 2026 - Volume 10, Issue 9 CRLF2 rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: a possible link? May 12 2026 - Volume 10, Issue 9 Field-testing the MALT-IPI in a single-center real-world cohort of patients with extranodal marginal zone lymphoma May 12 2026 - Volume 10, Issue 9 Causes of excess nonlymphoma death in 58 000 patients with DLBCL diagnosed during 1997 to 2020 and followed for up to 25 years May 12 2026 - Volume 10, Issue 9 Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis May 12 2026 - Volume 10, Issue 9 A monoclonal antibody to platelet αIIbβ3 that inhibits protein disulfide isomerase binding and platelet aggregation May 12 2026 - Volume 10, Issue 9 Multicenter initiative to standardize management of pediatric immune thrombocytopenia improves adherence to guidelines May 12 2026 - Volume 10, Issue 9 Mapping diagnostic practices in hemoglobinopathies: a cross-country HELIOS COST Action study May 12 2026 - Volume 10, Issue 9 Halofuginone suppresses hepcidin by a heparan sulfate-dependent mechanism to treat iron disorders in mice May 12 2026 - Volume 10, Issue 9 Newborn screening results for sickle cell disease from the ASH Consortium on Newborn Screening in Africa (CONSA) May 12 2026 - Volume 10, Issue 9 Novel use of a hash-based tokenization for sharing sickle cell disease data without sharing protected health information May 12 2026 - Volume 10, Issue 9 Development of a novel hemophilia A mouse model to study emicizumab and factor VIII inhibitor risk May 12 2026 - Volume 10, Issue 9 Volume electron microscopy reveals heterogeneity of the hemostatic response in veins and arteries May 12 2026 - Volume 10, Issue 9 Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome May 12 2026 - Volume 10, Issue 9 Anticoagulation, recurrent thrombosis, and major bleeding in antiphospholipid syndrome: UK multicenter observational study May 12 2026 - Volume 10, Issue 9 Complications in patients with cancer-associated thrombosis on tinzaparin by cancer site and frailty: a pooled analysis May 12 2026 - Volume 10, Issue 9 Apohemoglobin-haptoglobin complex is a therapeutic against vaso-occlusive crisis: scavenging of hemoglobin and heme May 12 2026 - Volume 10, Issue 9 Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS May 12 2026 - Volume 10, Issue 9 Outcome of second conditioned allogeneic stem cell transplant in children with non-SCID inborn errors of immunity May 12 2026 - Volume 10, Issue 9 Ferroportin inhibition attenuates pulmonary hypertension in hypoxic sickle cell disease mice May 12 2026 - Volume 10, Issue 9 Minimal disease detection by immunoglobulin high-throughput sequencing in pediatric Burkitt lymphoma May 12 2026 - Volume 10, Issue 9 Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM May 12 2026 - Volume 10, Issue 9 Exposure to Agent Orange and association with myelodysplastic syndromes May 12 2026 - Volume 10, Issue 9 Fiber intake associates with increased treatment response in patients with multiple myeloma along with changes in gut microbiome May 12 2026 - Volume 10, Issue 9 Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma May 12 2026 - Volume 10, Issue 9 Intensity of conditioning but not measurable residual disease status affects the outcomes of umbilical cord blood transplantation May 12 2026 - Volume 10, Issue 9 Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia May 12 2026 - Volume 10, Issue 9 Sickle cell pain: call for whole person health approaches to mechanisms-informed integrative management May 12 2026 - Volume 10, Issue 9 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts
New England Journal of Medicine, Volume 394, Issue 19, Page 1905-1915, May 14/21, 2026.
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial New England Journal of Medicine, Volume 394, Issue 19, Page 1916-1924, May 14/21, 2026.
Inflammatory Myopathies New England Journal of Medicine, Volume 394, Issue 19, Page 1925-1938, May 14/21, 2026.
Targeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathy New England Journal of Medicine, Volume 394, Issue 19, Page 1962-1963, May 14/21, 2026.
Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges New England Journal of Medicine, Volume 394, Issue 19, Page 1963-1964, May 14/21, 2026.
Current Causes of Death among Children and Adolescents in the United States New England Journal of Medicine, Volume 394, Issue 19, Page 1958-1959, May 14/21, 2026.
Endovascular Therapy for Medium-Vessel Occlusion Stroke — Narrowing the Target Population New England Journal of Medicine, Volume 394, Issue 19, Page 1955-1957, May 14/21, 2026.
Inhalation Injury from House Fire Smoke New England Journal of Medicine, Volume 394, Issue 19, May 14/21, 2026.
Central Retinal-Vein Occlusion New England Journal of Medicine, Volume 394, Issue 19, May 14/21, 2026.
How Did Race Get Into Lung Testing? New England Journal of Medicine, Volume 394, Issue 19, May 14/21, 2026.
Can AI Say “I Don’t Know”? New England Journal of Medicine, Volume 394, Issue 19, Page 1873-1875, May 14/21, 2026.
Overcoming the Digital Divide in Health Care AI New England Journal of Medicine, Volume 394, Issue 19, Page 1876-1877, May 14/21, 2026.
Prehospital Whole Blood in Traumatic Hemorrhage — a Randomized Controlled Trial New England Journal of Medicine, Ahead of Print.
Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease New England Journal of Medicine, Ahead of Print.
Intravascular Ultrasound–Guided or Angiography-Guided Complex High-Risk PCI New England Journal of Medicine, Ahead of Print.
Iptacopan in IgA Nephropathy — Final 24-Month Data New England Journal of Medicine, Ahead of Print.
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy New England Journal of Medicine, Ahead of Print.
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial New England Journal of Medicine, Ahead of Print.
Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock New England Journal of Medicine, Ahead of Print.
Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery New England Journal of Medicine, Ahead of Print.
Azithromycin for Preschoolers with Wheezing in the Emergency Department New England Journal of Medicine, Ahead of Print.
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation New England Journal of Medicine, Ahead of Print.
Clusters of Concern — Spatial Link between Childhood Undervaccination and Measles Outbreaks in South Carolina New England Journal of Medicine, Ahead of Print.
Sirolimus-Eluting Technology for the Treatment of Peripheral Artery Disease New England Journal of Medicine, Ahead of Print.
Left Atrial Appendage Closure — Should Recommendations Be Expanded? New England Journal of Medicine, Ahead of Print.
IVUS — A Zigzag Path to Success New England Journal of Medicine, Ahead of Print.
Money and Misdiagnosis New England Journal of Medicine, Ahead of Print.
Getting Serious about Tickborne Diseases — Shifting Research Priorities New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
Defining the Role of SABR in Head and Neck Cancer: Results from a Multi-institutional Delphi Consensus
The role of stereotactic ablative radiotherapy (SABR) in head and neck cancer remains uncertain. Historically used mainly for re-irradiation, its application in other clinical scenarios has expanded with recent advances.
Fri, 22 May 2026 00:00:00 -0700 Radiation dose-dependent skin toxicity and therapeutic advantage of FLASH radiotherapy via immune modulation FLASH radiotherapy shows promise in reducing normal tissue toxicity compared to conventional radiotherapy. Although several studies report skin-sparing effects of FLASH, few have quantitatively assessed this effect or explored underlying immunological mechanisms.
Fri, 22 May 2026 00:00:00 -0700 Longitudinal Plasma Proteomics Reveals an Immuno-thrombotic Signature that Predicts Radiation Pneumonitis in Lung Cancer Radiation pneumonitis (RP) is a dose-limiting toxicity in lung cancer radiotherapy, often poorly predicted by static clinical and dosimetric models. We aimed to identify a robust, blood-based proteomic signature grounded in the longitudinal biological response to radiation to enable accurate, early risk stratification.
Fri, 22 May 2026 00:00:00 -0700 Elective Nodal Radiotherapy in Localized Prostate Cancer: A Meta-Analysis Recently, results from NRG/RTOG 0924, the largest randomized trial to evaluate the benefit of whole-pelvic radiotherapy (WPRT) in localized prostate cancer, were presented. We conducted an aggregate meta-analysis of all phase III randomized trials to determine the impact of WPRT on oncologic outcomes.
Fri, 22 May 2026 00:00:00 -0700 Proton beam therapy for large localized hepatocellular carcinomas in western patients Optimal management of large, unresectable hepatocellular carcinoma (HCC) remains uncertain. Proton beam therapy (PBT) offers dosimetric advantages for sparing normal liver. Clinical outcomes for these patients in Western populations are limited. This study evaluated clinical outcomes, toxicity, and patterns of failure among Western patients with large localized HCC treated with PBT.
Fri, 22 May 2026 00:00:00 -0700 Radiotherapy de-escalation in breast cancer patients with pathologic complete response: An integrated analysis using real-world and simulated data Advances in neoadjuvant chemotherapy (NAC) have markedly increased pathologic complete response (pCR) rates in breast cancer, prompting reevaluation of the need for adjuvant radiotherapy (RT) in patients with excellent treatment response. The NSABP B-51 trial showed no survival benefit from regional nodal irradiation in patients achieving nodal pCR after NAC; whole-breast RT was still routinely delivered irrespective of breast response. Thus, the potential to safely omit RT in patients achieving breast pCR remains uncertain.
Thu, 21 May 2026 00:00:00 -0700 External Beam Radiotherapy (EBRT) & Immunotherapy (IO) in the Management of Hepatobiliary Malignancies: A Meta-analysis of Treatment Response Rates To evaluate in a meta-analysis the efficacy of external beam radiotherapy (EBRT) with immunotherapy (IO) in hepatobiliary malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), and identify factors associated with improved treatment response.
Thu, 21 May 2026 00:00:00 -0700 Long-term outcomes after proton therapy vs. intensity-modulated photon radiotherapy with concurrent chemotherapy for locally advanced non-small-cell lung cancer: post-hoc analysis of a prospective randomized trial To report long-term toxicity and disease outcomes from a randomized trial comparing passive-scattering proton therapy (PSPT) and intensity-modulated photon radiotherapy (IMRT), both with concurrent chemotherapy, for non-small-cell lung cancer (NSCLC).
Wed, 20 May 2026 00:00:00 -0700 Radiation-Induced Vaginal Stenosis in Cervical Cancer Patients in Low- and Middle-Income Countries: A Scoping Review Cervical cancer is the fourth most common cancer among women worldwide [1,2] with over 600,000 new cases and over 300,000 deaths annually [3]. The burden is disproportionately higher among women in low- and middle-income countries (LMICs), where more than 85% of cervical cancer-related deaths occur due to limited access to screening, Human Papillomavirus (HPV) vaccination, other HPV prevention strategies [3,4]. The global prevalence of cervical cancer is projected to increase by 14–17% by 2030 if no intervention is made to increase the availability of screening and protective vaccinations [5].
Wed, 20 May 2026 00:00:00 -0700 Measure What Matters: Rethinking Surrogate Metrics of Success in Radiation Oncology Census-based surrogates such as patients on treatment, fractions delivered, and course length have traditionally been used to assess radiation oncology departmental performance. These measures may no longer capture the complexities of modern radiotherapy, given the increased adoption of hypofractionation and stereotactic techniques. This study analyzes longitudinal trends in clinical operations, including treatment modalities, fractionation patterns, and financial performance, to identify value-based departmental performance metrics.
Wed, 20 May 2026 00:00:00 -0700 Non-invasive Reversible Software-based Electron FLASH Irradiation Configuration of a Linear Accelerator in Clinical Use Configuring clinical linear accelerators (linacs) for ultra-high dose rate (UHDR) electron experiments typically requires invasive hardware manipulation and/or irreversible modifications, limiting broader implementation. This work reports a reversible and non-invasive UHDR electron configuration of a clinical TrueBeam linac that enables switching between preclinical UHDR and conventional clinical treatment (CONV) modes through software settings, without accessing the linac interior.
Mon, 18 May 2026 00:00:00 -0700 Long-Term Outcomes of Reduced-Dose Radiotherapy in Patients with Epstein-Barr Virus DNA-Selected Stage III Nasopharyngeal Carcinoma: A 5-Year Follow-Up Secondary Analysis of a Phase II Trial We previously reported that reduced-dose (60 Gy) radiation was associated with favorable survival outcomes and limited toxicities in patients with low-risk stage III nasopharyngeal carcinoma (NPC) sensitive to induction chemotherapy (IC). However, the consistency of long-term outcomes remains unclear.
Sun, 17 May 2026 00:00:00 -0700 Technical Considerations on Proton Therapy in NRG's Multi-Institutional Clinical Trials Proton therapy is increasingly incorporated into clinical trials. However, its evolving technology and distinct physical and biological properties pose challenges for protocol design, treatment consistency, data collection and interpretation. This work outlines key technical considerations for implementing proton therapy in multi-institutional clinical trials and provides guidance to promote harmonized trial conduct and reliable data collection for outcome assessment.
Sun, 17 May 2026 00:00:00 -0700 MedNext-Insight Model for Automated Metabolic Tumor Volume Delineation on Computed Tomography and Prognostic Value in Nasopharyngeal Carcinoma : To develop a deep learning model for automated metabolic tumor volume (MTV) delineation on routine computed tomography (CT) without positron emission tomography (PET) and validate its prognostic value in nasopharyngeal carcinoma (NPC).
Sat, 16 May 2026 00:00:00 -0700 Peripheral PD-1⁺CD8⁺ T-cell TCR Dynamics During Radiation Therapy Predict Survival in Unresectable Locally Advanced Non-Small Cell Lung Cancer Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, reliable biomarkers for predicting response to immunotherapy remain limited. Among circulating immune cells, PD-1⁺CD8⁺ T cells represent an activated subset that directly responds to PD-1 blockade. Profiling the T-cell receptor (TCR) repertoire within this population may reflect antitumor immune activity and holds promise as noninvasive, blood-based biomarker.
Sat, 16 May 2026 00:00:00 -0700 Diabetes and Performance Status Predict Severe, Persistent Radiation Proctitis: Long-term Endoscopic Findings from STELLAR Trial To characterize the long-term endoscopic natural history of chronic radiation proctitis (CRP) and identify predictors of severe lesions in patients with locally advanced rectal cancer (LARC) from the STELLAR study.
Fri, 15 May 2026 00:00:00 -0700 |
BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions
Volume 31, Issue 6, June 2026, oyag165 Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors Volume 31, Issue 6, June 2026, oyag133 Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma Volume 31, Issue 6, June 2026, oyag159 Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products Volume 31, Issue 6, June 2026, oyag154 Adherence to oral antineoplastic agents, an overview and meta-analysis Volume 31, Issue 6, June 2026, oyag168 Trends in primary surgery and overall survival in non-metastatic anal cancer: a population-based analysis Volume 31, Issue 6, June 2026, oyag148 Female sex is associated with worse survival in laryngeal head and neck squamous cell carcinoma Volume 31, Issue 6, June 2026, oyag167 Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program Volume 31, Issue 6, June 2026, oyag169 Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in metastatic colorectal cancer Volume 31, Issue 6, June 2026, oyag142 Resilience in symptom response to cancer treatment: a new lens for examining variable symptom trajectories in older adults with advanced cancer Volume 31, Issue 6, June 2026, oyag094 Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis Volume 31, Issue 6, June 2026, oyag172 Immunotherapy with guts: a review of microbial therapeutic adjuncts for immunotherapy in solid tumors Volume 31, Issue 6, June 2026, oyag131 Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis Volume 31, Issue 6, June 2026, oyag137 Selective internal radiotherapy and chemosaturation show equivalent survival in metastatic uveal melanoma: a retrospective multicenter study Volume 31, Issue 6, June 2026, oyag152 Temozolomide reconsidered: Real-World evidence in resistant melanoma cases Volume 31, Issue 6, June 2026, oyag184 Exploring biologically-based complementary and alternative medicine use among Irish cancer survivors: findings from a national survey Volume 31, Issue 6, June 2026, oyag127 Clinical implications of variant allele frequencies of genes in patients with acute myeloid leukemia Volume 31, Issue 6, June 2026, oyag099 Outcomes of immunotherapy in medulloblastoma: a systematic review Volume 31, Issue 6, June 2026, oyag109 Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC Volume 31, Issue 6, June 2026, oyag151 Tumor growth rate as an intermediate trial endpoint Volume 31, Issue 6, June 2026, oyag149 |
The Price of Free Advice Diseases of the Colon & Rectum.69(5):733-735, May 2026. What Every Colorectal Surgeon Should Know About the Centers for Medicare and Medicaid Services Age-Friendly Hospital Measure Diseases of the Colon & Rectum.69(5):736-740, May 2026. Rupert B. Turnbull Jr, M.D., American Society of Colon and Rectal Surgeons President and Founder of The Cleveland Clinic Department of Colorectal Surgery Diseases of the Colon & Rectum.69(5):741-749, May 2026. Total and Tailored Mesorectal Excision for Rectal Cancer: Origins, Evolution, and Misconceptions Diseases of the Colon & Rectum.69(5):750-754, May 2026. Shared Decision-Making in Locally Advanced Rectal Cancer Diseases of the Colon & Rectum.69(5):755-758, May 2026. Expert Commentary on Shared Decision-Making in Rectal Cancer Diseases of the Colon & Rectum.69(5):759, May 2026. Stoma-Free Survival Following Low Anterior Resection With Coloanal Anastomosis for Stage II and III Rectal Cancer Diseases of the Colon & Rectum.69(5):760-767, May 2026. Utility of Transanal Total Mesorectal Excision in Patients With Obesity and Mid-to-Low Rectal Cancer: A Single-Center, Retrospective Cohort Study Diseases of the Colon & Rectum.69(5):768-777, May 2026. Biologics Before Surgery Are Not Associated With Complications After Surgery for IBD: A National Surgery Quality Improvement Program IBD Collaborative Causal Inference Analysis Diseases of the Colon & Rectum.69(5):778-791, May 2026. Treatment of Anal Fistula in Crohn’s Disease With Platelet-Rich Plasma: Long-term Results Diseases of the Colon & Rectum.69(5):792-800, May 2026. Patterns and Outcomes of Treatment Failure After Ligation of Intersphincteric Fistula Tract for Cryptoglandular Anal Fistula: Analysis of 200 Failed Ligation of the Intersphincteric Fistula Tract Cases Diseases of the Colon & Rectum.69(5):801-808, May 2026. Preliminary Results of Open Excisional Hemorrhoidectomy Combined With 3% Polidocanol Foam Sclerotherapy in Patients With Grade IV Hemorrhoidal Disease: A Randomized Controlled Open-Label Single-Center Study Diseases of the Colon & Rectum.69(5):809-818, May 2026. Autologous Platelet-Rich Plasma in Complex Anal Fistula Treatment: Getting It Right? Promising Clinical Data From 90 Patients Diseases of the Colon & Rectum.69(5):819-825, May 2026. Complications and Readmissions in Diverting Loop Ileostomies and Loop Colostomies Diseases of the Colon & Rectum.69(5):826-835, May 2026. Can Large Language Models Be a Viable Tool for Consensus Working Groups? Experience of the Ventral Rectopexy Expert Consensus Group Diseases of the Colon & Rectum.69(5):836-846, May 2026. Selected Abstracts Diseases of the Colon & Rectum.69(5):847-851, May 2026. Single-Port Robotic Abdominoperineal Resection and Bulky Lateral Lymph Node Dissection Via a Trans-stoma Site Approach Diseases of the Colon & Rectum.69(5):852-853, May 2026. From Instability to Strength: The “Laparoscopic Triple Compartment Sling” Solution for Multiple Compartmental Prolapse Diseases of the Colon & Rectum.69(5):854-855, May 2026. Laparoscopic Approach for Total Proctocolectomy With Ileoanal Pouch Reconstruction for Familial Polyposis Coli Diseases of the Colon & Rectum.69(5):856-857, May 2026. Remodified Hanley Technique for Horseshoe Abscess Diseases of the Colon & Rectum.69(5):858, May 2026. |
|
|
| |||
|
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response (pCR) in almost half of patients with stage I to III mismatch repair–deficient (dMMR) colon... Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen (PSA) screening is low in younger men—but rises sharply with age. The study, which aimed to estimate the impact of age on overdiagnosis of prostate cancer 15 years after screening stops, analyzed... Wednesday, April 29, 2026 10:35 AM FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd) (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive early-stage breast cancer. Monday, May 18, 2026 10:00 AM Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience New analyses from the multicenter phase III CAPItello-281 trial of the AKT1/2/3 inhibitor capivasertib plus the CYP17-inhibitor abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer—now sometimes described as androgen pathway modulation–resistant (APMR) (or modulation-sensitive ... Advanced Prostate Cancer: Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide In a post hoc analysis of the phase III ARCHES and PROSPER trials reported in the Journal of Clinical Oncology, Armstrong et al found that radiographic progression (rPD) often occurred without prostate-specific antigen (PSA) rise in patients with advanced prostate cancer receiving the androgen... Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Past Decade A new study shows that cases of stage IV breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published by Avila et al in JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly from 9.5... Monday, May 18, 2026 11:33 AM How Conquering Cancer Is a Team Effort After finishing her academic studies, Dr. Mittendorf enlisted in the U.S. Air Force—an experience that would propel her into the field of oncology. FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive Muscle-Invasive Bladder Cancer On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA... Friday, May 15, 2026 2:22 PM Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study Sigmoidoscopy screening led to reduced incidence of colorectal cancer, though more for men vs women, and a reduced rate of colorectal cancer–related mortality in men, according to findings from the randomized, controlled NORCCAP trial published in the Annals of Internal Medicine. Friday, May 15, 2026 12:00 PM Early Ovarian Cancer: Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival In a retrospective cohort study reported as a research letter in JAMA Oncology, Matsuo et al found an increasing use of minimally invasive surgery (MIS), an association of MIS with intraoperative capsule rupture, and an association of capsule rupture with poorer survival in patients with early... Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer In a systematic review and meta-analysis reported in JAMA Oncology, Miszczyk et al found that local therapies alone are associated with “reasonable efficacy” in select patients with locally radiorecurrent prostate cancer. Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients An international research team has shown that a specific subtype of diffuse large B-cell lymphoma (DLBCL) is associated with higher mortality risk in women than in men. The study was led by the laboratory of Ari Melnick, MD, Director of the Josep Carreras Leukaemia Research Institute and the Gebroe ... Friday, May 15, 2026 10:55 AM Relacorilant Plus Nab-Paclitaxel Improves Overall Survival in Platinum-Resistant Ovarian Cancer Final overall survival results from the phase III ROSELLA trial showed a statistically and clinically significant survival benefit with the selective glucocorticoid receptor antagonist relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer.... Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers? A systematic review and meta-analysis published in JAMA Network Open found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers. According to Inoue et al, this association appeared to be particularly pronounced in non–small cell lung... Thursday, May 14, 2026 11:09 AM Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonged overall survival in patients with bone-dominant metastatic castration-resistant prostate cancer... Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL On May 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sonrotoclax (Beqalzi), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. Wednesday, May 13, 2026 4:02 PM FDA Approves Combination Regimen for Newly Diagnosed AML On May 13, the U.S. Food and Drug Administration (FDA) approved an oral combination of decitabine and cedazuridine tablets (Inqovi) plus venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older or who have comorbidities that preclude them from... Wednesday, May 13, 2026 4:00 PM Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Hundreds of thousands of people diagnosed with cancer are still alive today, but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those diagnosed today to carry a germline... Wednesday, May 13, 2026 1:48 PM Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality Long-term exposure to air pollution significantly increases both the risk of developing cancer and the likelihood of dying from the disease, according to a new global evidence report released by the Union for International Cancer Control (UICC), titled Clean air in cancer control: An overview of... Tuesday, April 28, 2026 11:26 AM Addition of Toripalimab to Perioperative Chemotherapy in Locally Advanced Gastric or Gastroesophageal Junction Cancer In an update of a Chinese phase II trial (NEOSUMMIT-01) reported in the Journal of Clinical Oncology, Nie et al found that the addition of the anti–PD-1 antibody toripalimab to perioperative chemotherapy improved 3-year event-free and overall survival in patients with locally advanced gastric or... Inherited Long Telomeres May Increase the Risk of Lymphoid Cancers Researchers at the Johns Hopkins Kimmel Cancer Center and the Telomere Clinic at Johns Hopkins have identified a genetic syndrome in which unusually long telomeres—the protective caps at the ends of chromosomes—allow immune cells to remain biologically “younger” for longer than normal, predisposing ... Wednesday, May 13, 2026 12:28 PM Inflammatory Breast Cancer: Blood-Based Biomarkers Identified Researchers have identified blood-based biomarkers in tumors, peripheral blood cells, and plasma that may help to differentiate between inflammatory breast cancer and non–inflammatory breast cancer, according to findings published in Science Advances. Wednesday, May 13, 2026 10:00 AM COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) had longer survival compared to national benchmarks when treated in independent community oncology practices, according to a new study commissioned by the Community Oncology Alliance (COA) and conducted by... Monday, May 4, 2026 12:51 PM Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults In a cohort study reported in JAMA Oncology, Fox et al found that approximately half of older patients with metastatic non–small cell lung cancer (NSCLC) have received systemic therapy in the United States in recent years. New Whole-Genome Sequencing Test Enables Genomically Informed Treatment Decision-Making in Multiple Myeloma A clinical whole-genome sequencing test for patients with multiple myeloma, JAYseq, has been launched at the Translational Genomics Research Institute (TGen). Tuesday, May 12, 2026 1:00 PM Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5039). The researchers... Monday, April 27, 2026 12:15 PM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC
Kidney injury molecule-1 (KIM-1) is overexpressed in renal cell carcinoma (RCC), and consistent shedding of this cell-surface protein into the circulation makes it a promising blood-based biomarker for this disease. Herein, we outline potential roles of circulating KIM-1 in diagnosis, prognostication and therapeutic monitoring of RCC, as well as research priorities for clinical translation of this biomarker. Wed, 20 May 2026 00:00:00 -0700 Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons The management of gastro-oesophageal adenocarcinoma (GEA) is undergoing substantial changes owing to evolving treatment paradigms and new therapeutic strategies on the background of a shifting global epidemiology. This Review discusses the state-of-the-art perioperative management of resectable GEA, with an emphasis on how biological heterogeneity influences geographical practice patterns, and outlines future directions for research including precision medicine approaches, biomarker-guided immunotherapy and tailored surgical approaches. Fri, 15 May 2026 00:00:00 -0700 Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer Thu, 14 May 2026 00:00:00 -0700 Clinical implementation of multi-cancer early detection tests: can we find a path forward? On 3 February 2026, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was enacted, enabling Medicare coverage for multi-cancer early detection (MCED) tests. This legislation coincides with new results from key clinical trials and has important implications for payers and policymakers, given the lack of FDA approval of any MCED test or evidence that population screening with such tests reduces cancer-related or all-cause mortality. Thu, 14 May 2026 00:00:00 -0700 Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer The historical development of plasma Epstein–Barr virus DNA for informing clinical decisions for patients with nasopharyngeal carcinoma has culminated in the EP-STAR trial. The circulating tumour DNA clearance patterns observed during neoadjuvant chemotherapy could be used to guide adjuvant therapy, improve outcomes and possibly reflect differences in tumour biology. Herein we discuss why this study constitutes a full-circle moment and provides valuable insights for advancing circulating tumour DNA-based applications in precision oncology. Wed, 06 May 2026 00:00:00 -0700 The transformative role of SBRT in the management of spinal metastases Spinal metastases are associated with debilitating pain and neurological deterioration as well as a poor prognosis and have historically been managed with a palliative intent. Now, following the emergence of stereotactic body radiotherapy (SBRT), more effective pain control as well as control of the metastatic lesions is becoming feasible. In this Review, the authors describe the development and role of SBRT in the management of spinal metastases. Tue, 05 May 2026 00:00:00 -0700 Synergistic integration of regional and systemic therapies in uveal melanoma Treatments for metastatic uveal melanoma utilize various liver-directed strategies, yet optimal integration with systemic therapy is unclear. Here we examine recent evidence indicating that combining percutaneous hepatic perfusion with immune-checkpoint inhibitors might improve patient outcomes, compare it with data from other trials and highlight key questions around patient selection, sequencing and mechanisms that will shape future strategies. Wed, 29 Apr 2026 00:00:00 -0700 Emerging trends in the global burden of colorectal cancer The incidence of colorectal cancer (CRC) has historically been the highest among Western, high-income countries but is now increasing globally beyond these regions. Early-onset CRC (diagnosed before the age of 50 years) has been the main driver of this rise, and risk factors including dietary and lifestyle aspects, the gut microbiota and environmental contaminants have been proposed to underlie these epidemiological trends. The authors of this Review discuss the available evidence on these risk factors, highlighting how the under-representation of non-Western populations in these studies is limiting progress. Tue, 28 Apr 2026 00:00:00 -0700 |
|
|
| |||
|
Predictive model based on folate receptor-positive circulating tumor cells in neoadjuvant immunochemotherapy for esophageal cancer
Vol 17, No 2 (April 30, 2026): Neoadjuvant adebrelimab combined with triplet chemotherapy for locally advanced resectable adenocarcinoma of esophagogastric junction: a prospective, single-arm, phase II feasibility and safety study Vol 17, No 2 (April 30, 2026): The prevalence of gastric intestinal metaplasia in the Saudi population: a single-tertiary center retrospective study Vol 17, No 2 (April 30, 2026): Prognostic impact of low absolute skeletal muscle mass 6 months after gastrectomy for gastric cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Diagnostic value of mini-probe endoscopic ultrasound in preoperative tumor nodal (TN) staging of gastric cancer and analysis of factors influencing T-staging accuracy Vol 17, No 2 (April 30, 2026): Transcatheter arterial embolization with N-butyl cyanoacrylate versus gelatin sponge particles for gastric cancer-related upper gastrointestinal bleeding: a comparison of efficacy and safety Vol 17, No 2 (April 30, 2026): Postoperative frailty among elderly patients undergoing radical surgery for gastrointestinal tumors and its relationship with prognosis Vol 17, No 2 (April 30, 2026): Molecular characteristics and metastatic mechanism of patients diagnosed with Krukenberg tumor from gastric cancer Vol 17, No 2 (April 30, 2026): Retrospective study on clinical outcomes and safety evaluation of da Vinci robot-assisted laparoscopy and endoscopic cooperative for small gastric stromal tumors resection: preliminary single-center experience Vol 17, No 2 (April 30, 2026): The impact of ulinastatin on postoperative clinical outcomes in patients with gastric cancer: a retrospective cohort analysis Vol 17, No 2 (April 30, 2026): Comparison of the efficacy and safety of single-incision versus multi-port laparoscopic D2 lymphadenectomy for locally advanced gastric cancer: a systematic review and meta-analysis Vol 17, No 2 (April 30, 2026): Development and external validation of a prognostic nomogram for cancer-specific survival in elderly patients with early-stage gastric cancer Vol 17, No 2 (April 30, 2026): Identification of immunogenic cell death-related prognostic genes in gastric cancer Vol 17, No 2 (April 30, 2026): Opportunistic CT screening for osteosarcopenia predicts reduced overall survival in patients with gastric cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Patterns of recurrence and outcomes of poor responders to neoadjuvant long-course chemoradiotherapy for rectal cancer Vol 17, No 2 (April 30, 2026): Identification of an autophagy-related prognostic signature and validation of WDR45 in colorectal cancer Vol 17, No 2 (April 30, 2026): KRAS mutation subtypes refine prognostic stratification in colorectal cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Development and validation of manganese metabolism-related genes prognostic model in colorectal cancer and its immunological characteristics Vol 17, No 2 (April 30, 2026): Intratumoral PKM2 expression predicts benefit from adjuvant FOLFOX in stage II–III colorectal cancer Vol 17, No 2 (April 30, 2026): Assessment of colorectal cancer recurrence risk following solid organ transplantation Vol 17, No 2 (April 30, 2026): CCL5 promotes colon cancer progression via PI3K/AKT signaling and is negatively regulated by STAT1 Vol 17, No 2 (April 30, 2026): Molecular subtyping and prognostic model construction based on endosome-related genes in colorectal cancer Vol 17, No 2 (April 30, 2026): No survival benefit from adjuvant chemotherapy in high-risk stage II small intestinal adenocarcinoma after surgery: a population-based long-term survival analysis Vol 17, No 2 (April 30, 2026): Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience Vol 17, No 2 (April 30, 2026): Single-cell transcriptome analysis identifies neutrophil-related prognostic signatures in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): TRNP1 regulates tumorigenesis and enhances immunotherapy response via c-Kit/STAT3 signaling in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Perioperative clinicopathologic model for predicting 12-month early recurrence after curative hepatectomy in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Association of serum lactate dehydrogenase levels with the severity of microvascular invasion in hepatocellular carcinoma: a retrospective cross-sectional study Vol 17, No 2 (April 30, 2026): An exploratory nomogram model with 18F-FDG PET/CT metabolic parameters for predicting high-risk status of microvascular invasion in hepatocellular carcinoma patients prior to liver transplantation Vol 17, No 2 (April 30, 2026): Impact of tumor mutation burden on the prognosis of patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs Vol 17, No 2 (April 30, 2026): Prognostic genes in hepatocellular carcinoma and their function: an analysis integrating high-throughput-based spatial transcriptomics and single-cell RNA-sequencing Vol 17, No 2 (April 30, 2026): PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Development and validation of a model for predicting short-term complications after hepatectomy in patients with primary liver cancer Vol 17, No 2 (April 30, 2026): Temporal change in liver function after stereotactic body radiation therapy for hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): A novel deep learning and radiomics approach based on DCE-MRI for predicting the P53 mutation status in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Peripheral regulatory T cells trajectory predicts progression-free survival in hepatocellular carcinoma patients during on-demand transarterial chemoembolization using joint model: a prospective study Vol 17, No 2 (April 30, 2026): PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study Vol 17, No 2 (April 30, 2026): Indeterminate nodule-like arterial phase hyperenhancement in the liver on CT: differentiation of hepatocellular carcinomas from vascular pseudolesions using a CT radiomics approach Vol 17, No 2 (April 30, 2026): Association between primary tumor resection and survival in metastatic intrahepatic cholangiocarcinoma: a retrospective cohort study based on the SEER database Vol 17, No 2 (April 30, 2026): Multi-scale deep learning models based on MRI for predicting pathological differentiation and evaluating its association with recurrence-free survival in hepatocellular carcinoma: an explainable machine learning study Vol 17, No 2 (April 30, 2026): Daily increment of residual liver regeneration (DIRER) predicts tumor recurrence and mortality after radical hepatectomy for hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Silencing OTUB1 induces pyroptosis to inhibit the growth of liver cancer HepG2 cells via the NLRP3/caspase/GSDM signaling pathway Vol 17, No 2 (April 30, 2026): Targeting AKR1C1 overcomes lenvatinib resistance in hepatocellular carcinoma through the STAT3-ABC transporters pathway Vol 17, No 2 (April 30, 2026): Multi-institutional care is associated with improved survival in biliary tract cancer Vol 17, No 2 (April 30, 2026): Development and validation of machine learning models integrating spectral computed tomography-derived three-dimensional quantitative parameters for predicting histopathological grade in pancreatic ductal adenocarcinoma Vol 17, No 2 (April 30, 2026): A biomarker-integrated nomogram for predicting postoperative pancreatic fistula in low- to intermediate-risk patients after pancreaticoduodenectomy Vol 17, No 2 (April 30, 2026): Impact of preoperative body weight on short-term and long-term prognosis after pancreatic resection for pancreatic ductal adenocarcinoma: a multicenter study Vol 17, No 2 (April 30, 2026): A TRPM4-associated necrotic cell death signature for prognostic stratification in pancreatic cancer Vol 17, No 2 (April 30, 2026): Single-nucleus RNA sequencing reveals the effects of key regulators on human pancreatic adenocarcinoma and its tumor microenvironment Vol 17, No 2 (April 30, 2026): Neoadjuvant radiotherapy after chemotherapy does not improve surgical or survival outcomes in borderline resectable pancreatic cancer Vol 17, No 2 (April 30, 2026): A systematic review of artificial intelligence and machine learning for gut microbiome-based CRC screening Vol 17, No 2 (April 30, 2026): Multimodal data-driven prediction of postoperative recurrence and survival in hepatocellular carcinoma: a narrative review Vol 17, No 2 (April 30, 2026): Risk factors for exclusive lung metastasis in colorectal cancer: a comprehensive narrative review Vol 17, No 2 (April 30, 2026): Advances in mitophagy research in hepatocellular carcinoma: mechanisms and therapeutic implications Vol 17, No 2 (April 30, 2026): A case report of rectal squamous cell carcinoma following radiation therapy for prostate cancer: a management dilemma Vol 17, No 2 (April 30, 2026): Diagnostic challenges in gastrointestinal stromal tumors: a case report of concurrent gastrointestinal stromal tumor, lymphangioma, and solid pseudopapillary neoplasm of the pancreas Vol 17, No 2 (April 30, 2026): Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report Vol 17, No 2 (April 30, 2026): Gastric lymphoma presenting with predominant pancreatitis and cranial neuropathy: a rare clinical presentation—a case report Vol 17, No 2 (April 30, 2026): A case report of gastroesophageal adenocarcinoma with yolk sac tumor differentiation in a pregnant patient Vol 17, No 2 (April 30, 2026): The underestimated global burden and projections of early-onset stomach and early-onset esophageal cancers Vol 17, No 2 (April 30, 2026): Impact of maintenance therapy with fluoropyrimidines in advanced esophageal-gastric adenocarcinoma: a critical review Vol 17, No 2 (April 30, 2026): Methodological clarifications on maintenance fluoropyrimidines in advanced esophagogastric adenocarcinoma: a real-world Mexican cohort Vol 17, No 2 (April 30, 2026): Fruquintinib in refractory metastatic colorectal cancer: separating randomized trial evidence from observational data Vol 17, No 2 (April 30, 2026): Interpreting the evidence base for fruquintinib in refractory metastatic colorectal cancer Vol 17, No 2 (April 30, 2026): Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151 Vol 17, No 2 (April 30, 2026): Personalised neoadjuvant therapy, based on tumour characteristics and patient choice, is the best way forward in rectal cancer Vol 17, No 2 (April 30, 2026): Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? —a decade of debate! Vol 17, No 2 (April 30, 2026): Emerging mechanisms of kinase inhibitor escape and clinical implications of ponatinib in advanced gastrointestinal stromal tumor Vol 17, No 2 (April 30, 2026): When precision medicine meets human behavior: limits of artificial intelligence in predicting imatinib adherence Vol 17, No 2 (April 30, 2026): Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Muscling in on body surface area to reduce oxaliplatin-induced peripheral neuropathy in colon cancer Vol 17, No 2 (April 30, 2026): Clearing the bar: adding anti-VEGF therapy to chemoimmunotherapy for biliary tract cancer Vol 17, No 2 (April 30, 2026): Maximizing the “toolbox” for patients with initially unresectable colorectal liver metastases: have liver mets “met” their match? Vol 17, No 2 (April 30, 2026): The 12-node rule in irradiated rectal cancer: time for reappraisal? Vol 17, No 2 (April 30, 2026): Beyond drug toxicity: the hidden burden of financial toxicity in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Gastrointestinal malignancies in pregnancy: practical considerations Vol 17, No 2 (April 30, 2026): Intrahepatic cholangiocarcinoma: the equity gap in one of the most lethal cancers Vol 17, No 2 (April 30, 2026): Adjuvant chemotherapy in elderly colon cancer patients: when less may be more Vol 17, No 2 (April 30, 2026): Sarcopenia in esophageal cancer: from passive prognostic marker to active treatment target Vol 17, No 2 (April 30, 2026): Return on investment, return of risk: private equity in gastrointestinal cancer care Vol 17, No 2 (April 30, 2026): Tumor necrosis as a key refinement of risk stratification in gastric gastrointestinal stromal tumors Vol 17, No 2 (April 30, 2026): Survival outcomes in early gastric cancer: evidence from SEER-based population studies Vol 17, No 2 (April 30, 2026): Spontaneous rupture of hepatocellular carcinoma: mechanobiology, rescue, and oncologic control Vol 17, No 2 (April 30, 2026): From waste to wealth: malignant ascites-derived organoids as a compass for precision therapy in advanced gastrointestinal cancers Vol 17, No 2 (April 30, 2026): Erratum: Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings Vol 17, No 2 (April 30, 2026): Retraction: Interfering HMGB3 release from cancer-associated fibroblasts by miR-200b represses chemoresistance and epithelial-mesenchymal transition of gastric cancer cells Vol 17, No 2 (April 30, 2026): |
Robotic Hepatic Artery Infusion Pump Placement after Recurrent Colorectal Liver Metastasis following Open Left Hemihepatectomy
Wed, 20 May 2026 00:00:00 -0700 Leaving the Axilla Untouched: Toward Surgical De-escalation in Early Luminal A Breast Cancer Wed, 20 May 2026 00:00:00 -0700 Correction: Assessing Recent Trends in Lumpectomy and Concomitant Oncoplastic Procedures: A National Insurance Database Analysis Tue, 19 May 2026 00:00:00 -0700 ASO Author Reflections: Revealing Hidden Liver Anatomy Through ICG-Visualized Venous Congestion Tue, 19 May 2026 00:00:00 -0700 ASO Author Reflections: Avoiding Mobilization in Laparoscopic Surgery for Huge Hepatocellular Carcinoma in the Right Posterior Section Tue, 19 May 2026 00:00:00 -0700 ASO Visual Abstract: Psoas Muscle Well-Differentiated Liposarcoma: A Distinct Anatomic Subset with Highly Favorable Outcomes Tue, 19 May 2026 00:00:00 -0700 ICG-Enhanced Visualization of Venous Congestion for Laparoscopic Anatomical Liver Resection of Segment 8-Ventral Tue, 19 May 2026 00:00:00 -0700 Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival Tue, 19 May 2026 00:00:00 -0700 Efficacy of Adjuvant Chemoimmunotherapy versus Chemotherapy and the Impact of Lymph Node Dissection on Survival Tue, 19 May 2026 00:00:00 -0700 ASO Author Reflections: Integrating Stereotactic Body Radiation into Modern Chemotherapy for Locally Advanced Pancreatic Cancer Sun, 17 May 2026 00:00:00 -0700 ASO Author Reflections: Early Disease-Related Mortality After Neoadjuvant Therapy and Radical Resection for Pancreatic Ductal Adenocarcinoma—The Biological Burden Beyond Resectability Sun, 17 May 2026 00:00:00 -0700 ASO Author Reflections: Beyond Cosmetic Success—Restoring Sensation in Nipple-Sparing Mastectomy Sun, 17 May 2026 00:00:00 -0700 Beyond CheckMate 577: Risk Stratification of Postoperative Recurrence after Adjuvant Nivolumab in Esophageal Cancer Sun, 17 May 2026 00:00:00 -0700 Robotic-Assisted Cytoreductive Surgery for Recurrent Endometrial Carcinoma with Iliac Vessel Involvement: A Multidisciplinary Approach Sun, 17 May 2026 00:00:00 -0700 Letter to the Editor: Comment on “Evaluating C-Reactive Protein in Drainage Fluid as a Predictive Biomarker for Clinically Relevant Pancreatic Fistulas following Pancreaticoduodenectomy” Sun, 17 May 2026 00:00:00 -0700 ASO Author Reflections: Decision Analysis in the Era of Evolving Guidelines for Branch-Duct IPMN Sun, 17 May 2026 00:00:00 -0700 Laparoscopic Anterior-Approach Right Posterior Sectionectomy for Huge Hepatocellular Carcinoma: Technique and Short-Term Outcomes Sun, 17 May 2026 00:00:00 -0700 Years of Life Lost in Patients with Muscle-Invasive and Metastatic Bladder Cancer Sun, 17 May 2026 00:00:00 -0700 Combined Association of Time to Treatment, Guideline Concordance, and Neighborhood Vulnerability with Localized Colon Cancer, Non-small-cell Lung Cancer, and Pancreatic Cancer Survival Sun, 17 May 2026 00:00:00 -0700 Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma—A Distinct Entity Conferring Better Prognosis and Requiring Therapeutic Paradigm Shift Fri, 15 May 2026 00:00:00 -0700 Fluorescence-Guided Remnant-Sparing Laparoscopic Distal Pancreatectomy for Metachronous Pancreatic Cancer Following Whipple Procedure Fri, 15 May 2026 00:00:00 -0700 Biomarker-Driven Management of Nonmetastatic GEJ Adenocarcinoma Fri, 15 May 2026 00:00:00 -0700 ASO Visual Abstract: Exploring the Limits of Perigastric Surgery in CRS and HIPEC for Pseudomyxoma Peritonei: A Functional Burden with Preserved Oncologic Outcomes Thu, 14 May 2026 00:00:00 -0700 ASO Author Reflections: When Anatomy Misleads—Stepwise Oncologic Strategy for Pancreaticoduodenectomy in Complete Situs Inversus with a Common Mesentery Thu, 14 May 2026 00:00:00 -0700 ASO Author Reflections: From Tumor Downstaging to Functional Preservation—A New Paradigm in Hypopharyngeal Cancer Thu, 14 May 2026 00:00:00 -0700 Sentinel Lymph Node Positivity and Utility of Frozen Section Diagnosis following Neoadjuvant Therapy in Patients with Clinically Node-Negative, Hormone Receptor-Positive, HER2-Negative Breast Cancer Thu, 14 May 2026 00:00:00 -0700 Artificial Intelligence-Driven Three-Dimensional Reconstruction System Reduced Unexpected Procedural Changes in Thoracic Surgery Thu, 14 May 2026 00:00:00 -0700 Patient and Tumor Factors Influencing Diagnostic Trajectories in Gastrointestinal Stromal Tumor Patients and Their Impact on Health-Related Quality of Life: A Dutch Multicenter Study Thu, 14 May 2026 00:00:00 -0700 High-Volume Anesthesiologist and Surgeon Teams are Associated with Lower Operating Room Charges for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Thu, 14 May 2026 00:00:00 -0700 Identifying Predictors of Delayed Ambulation After Minimally Invasive Gynecologic Oncology Surgery Thu, 14 May 2026 00:00:00 -0700 From Clinical Trial Awareness to Practice: Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Clinical Trial Thu, 14 May 2026 00:00:00 -0700 Clinical Course and Dedifferentiation of Atypical Lipomatous Tumors: A Retrospective Analysis of Surveillance and Surgical Management Wed, 13 May 2026 00:00:00 -0700 Blindly Trusting the Stage: The Therapeutic Consequences of Clinical Staging Inaccuracy in Gastric Cancer Wed, 13 May 2026 00:00:00 -0700 ASO Visual Abstract: Immunochemotherapy Versus Chemoradiotherapy Followed by Conversion Surgery for Initially Unresectable Stage cT4 Esophageal Squamous Cell Carcinoma Tue, 12 May 2026 00:00:00 -0700 Evolution of Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases Tue, 12 May 2026 00:00:00 -0700 ASO Author Reflections: Onward with Sentinel Lymph Node Omission: Implications of SOUND and INSEMA Trials for Mastectomy Patients Tue, 12 May 2026 00:00:00 -0700 ASO Author Reflections: Calibrating Lymph Node Metastasis Risk After Non-curative Endoscopic Resection of pT1 Colorectal Cancer Tue, 12 May 2026 00:00:00 -0700 ASO Author Reflections: Robotic Cytoreduction at the Vascular Interface: Redefining Surgical Limits Tue, 12 May 2026 00:00:00 -0700 Structured Adaptability in HPB Cancer Surgery: Precision Beyond Technical Uniformity Tue, 12 May 2026 00:00:00 -0700 Clinical Course and Risk Factors for Malignant Progression in Intraductal Papillary Mucinous Neoplasms with High-Risk Stigmata Tue, 12 May 2026 00:00:00 -0700 Engineered Exosomes for Delivery of Mir-423-5p to Improve Radiation Sensitivity by Inhibiting MAP7D1 in Esophageal Cancer Tue, 12 May 2026 00:00:00 -0700 ASO Visual Abstract: Do Postoperative Complications Impact Adjuvant Chemotherapy for Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Mon, 11 May 2026 00:00:00 -0700 ASO Visual Abstract: Association Between Clinical Tumor Stage and Response to Total Neoadjuvant Therapy in Rectal Cancer: Outcomes in cT3 Versus cT4 Disease Mon, 11 May 2026 00:00:00 -0700 ASO Author Reflections: Radical Resection for HCC with PVTT After Second-Line Conversion Therapy Mon, 11 May 2026 00:00:00 -0700 ASO Visual Abstract: High PARP7 Expression is Associated with Higher Estrogen Response and Immune Suppression but Less Cell Proliferation and Better Survival in Breast Cancer Mon, 11 May 2026 00:00:00 -0700 ASO Visual Abstract: Prognosis After Curative Resection of Esophageal Basaloid Squamous Cell Carcinoma: A Single-Institution Retrospective Study Mon, 11 May 2026 00:00:00 -0700 PneumoScore: A Novel Risk Prediction Model for 90-Day Mortality after Lung Resection Mon, 11 May 2026 00:00:00 -0700 Beyond “High Risk”: Toward Individualized Decision-Making After Noncurative Endoscopic Resection of T1 Colorectal Cancer Mon, 11 May 2026 00:00:00 -0700 Locoregional Control from Complete Peritoneal Cytoreduction in Patients with Extraperitoneal Colorectal Cancer Metastases: An Entropy Balanced Analysis Mon, 11 May 2026 00:00:00 -0700 Utility of 21-Gene Recurrence Score in Male Breast Cancer Mon, 11 May 2026 00:00:00 -0700 |
||
|
| |||
|
What You May Have Missed in 2025
Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Cardiology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Endocrinology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Gastroenterology/Hepatology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Infectious Diseases: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Nephrology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Oncology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Pulmonology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Rheumatology: What You May Have Missed in 2025 Annals of Internal Medicine, Volume 179, Issue 5_Supplement, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID Annals of Internal Medicine, Volume 179, Issue 5, Page 621-628, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Short Versus Longer Antibiotic Duration for Community-Acquired Pneumonia Annals of Internal Medicine, Volume 179, Issue 5, Page 629-636, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Firearm Acquisition and New Exposure to Household Firearms After the Initial Pandemic Purchasing Surge: Results From the 2024 National Firearms Survey Annals of Internal Medicine, Volume 179, Issue 5, Page 637-644, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Multisite External Validation of a Clinical Screening Tool for Interpersonal Firearm Violence Risk Annals of Internal Medicine, Volume 179, Issue 5, Page 645-655, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain Annals of Internal Medicine, Volume 179, Issue 5, Page 656-665, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Functional Status of Adults at Risk of Medicaid Disenrollment Under National Work Requirements Annals of Internal Medicine, Volume 179, Issue 5, Page 666-672, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 673-684, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 685-695, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Prevention of Recurrent Nephrolithiasis in Adults and Children Annals of Internal Medicine, Volume 179, Issue 5, Page 696-707, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Determining the Conclusiveness of Systematic Review Evidence Annals of Internal Medicine, Volume 179, Issue 5, Page 708-720, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 COVID-19 Vaccines for 2025–2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 728-733, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 734-739, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Fostering Support and Inclusion for Physicians, Postgraduate Trainees, and Medical Students With Disabilities: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 721-724, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Improving the Health of and Access to Health Care for People With Disabilities: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 5, Page 725-727, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Dementia: Clinical Challenges Annals of Internal Medicine, Volume 179, Issue 5, Page 740-741, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 Incentivizing Deprescribing for Health Care Quality Not Quantity Annals of Internal Medicine, Volume 179, Issue 5, Page 742-743, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 The Current Threat to the U.S. Preventive Services Task Force and Why It Matters Annals of Internal Medicine, Volume 179, Issue 5, Page 744-745, May 2026. <br/> Tue, 14 Apr 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop
Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.
Relay doubles the bar, outpacing Novartis with a 60% response in rare disease Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval.
Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts eager for more data.
Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset—a number that fell short of the company’s prior guidance of a double-digit improvement.
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis.
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears Corcept Therapeutics’ amyotrophic lateral sclerosis drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.
Novartis, PTC push Huntington’s drug into Phase 3, mum on accelerated approval Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more than 50%. Analysts say the decision to initiate a last-stage trial reflects a lack of confidence in an accelerated FDA nod.
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting 858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026 Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026 Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial ASCO 2026: Bayer to Present New Data Across Oncology Portfolio Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting |
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication After being hit by safety issues and subpar results in another trial, BioMarin’s Phase 3 test of Voxzogo for a rare skeletal disorder called hypochondroplasia showed efficacy “solidly above” what the drug has shown for achondroplasia, which causes dwarfism.
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop BioMarin’s investigational therapy failed to elicit clinical improvements in patients with ENPP1 deficiency, while also missing key secondary endpoints of rickets severity and growth.
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer Merck and Kelun-Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial cancer study, though the companies have yet to specify when they plan to file for approval.
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3 The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also noting last year’s Phase 3 failure in chronic obstructive pulmonary disease.
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
Viridian turns green again as new Phase 3 data vindicate thyroid eye disease drug Viridian Therapeutics’ elegrobart normalized the degree of eye protrusion and improved double vision in a Phase 3 study. The company plans to file for approval in the first quarter of 2027.
Summit shares descend as PD-1/VEGF asset misses early survival mark Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders.
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting Caliway Announces U.S. FDA IND Clearance for CBL-0302, Its Second Global Pivotal Phase 3 Study of CBL-514 OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO’s Partner in China Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 IntraBio Receives Regulatory Authorization to Begin Pivotal Phase III Trial of Levacetylleucine in CACNA1A-Related Disorders Across Participating Regions Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC |
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos Kissei Pharmaceutical is reversing a recommendation related to Amgen-shared Tavneos that it made just a few days ago, now saying the rare disease drug can be given to new patients.
BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication After being hit by safety issues and subpar results in another trial, BioMarin’s Phase 3 test of Voxzogo for a rare skeletal disorder called hypochondroplasia showed efficacy “solidly above” what the drug has shown for achondroplasia, which causes dwarfism.
Inside Germany’s biotech capital infrastructure and innovation engine In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They explore Germany’s biotech and life sciences ecosystem, including the science, infrastructure and policy changes needed to help European companies scale globally while staying rooted in Europe.
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.
Relay doubles the bar, outpacing Novartis with a 60% response in rare disease Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval.
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop BioMarin’s investigational therapy failed to elicit clinical improvements in patients with ENPP1 deficiency, while also missing key secondary endpoints of rickets severity and growth.
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer Merck and Kelun-Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial cancer study, though the companies have yet to specify when they plan to file for approval.
Is Revolution ‘the next oncology titan’? Truist analysts make the case A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said Revolution Medicines “is evolving into a major revenue-generating oncology company,” and projects an approval in second-line disease by the end of the third quarter.
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026 Caliway Announces U.S. FDA IND Clearance for CBL-0302, Its Second Global Pivotal Phase 3 Study of CBL-514 OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting 858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026 Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC |
|
|
| |||
|
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer
On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Fri, 22 May 2026 00:00:02 -0700
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
Fri, 15 May 2026 00:00:02 -0700
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
Fri, 15 May 2026 00:00:02 -0700
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Wed, 13 May 2026 00:00:02 -0700
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Wed, 13 May 2026 00:00:02 -0700
FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
Fri, 08 May 2026 00:00:02 -0700
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Fri, 01 May 2026 00:00:02 -0700
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Wed, 25 Mar 2026 00:00:02 -0700
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
Fri, 20 Mar 2026 00:00:02 -0700
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 05 Mar 2026 00:00:02 -0800
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Thu, 26 Feb 2026 00:00:02 -0800
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
Tue, 24 Feb 2026 00:00:02 -0800
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Thu, 19 Feb 2026 00:00:02 -0800
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Tue, 10 Feb 2026 00:00:02 -0800
Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency Thu, 05 Feb 2026 00:00:02 -0800
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Tue, 27 Jan 2026 00:00:02 -0800
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
Wed, 17 Dec 2025 00:00:02 -0800
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).
Wed, 17 Dec 2025 00:00:02 -0800
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
Mon, 15 Dec 2025 00:00:02 -0800
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
Fri, 12 Dec 2025 00:00:02 -0800
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy
Thu, 04 Dec 2025 00:00:02 -0800
FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Wed, 03 Dec 2025 00:00:02 -0800
FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Tue, 25 Nov 2025 00:00:02 -0800
FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.
Fri, 21 Nov 2025 00:00:02 -0800
|
Updated trends in the global prevalence and burden of mental disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Lancet. 2026 May 23;407(10543):2040-2064. doi: 10.1016/S0140-6736(26)00519-2. GBD 2023 Mental Disorder Collaborators Observation of a superfluid-to-insulator transition of bilayer excitons. Nature. 2026 Feb;650(8100):86-92. doi: 10.1038/s41586-025-09986-w. Epub 2026 Jan 28. Zeng Y, Sun D, Zhang NJ, Nguyen RQ, Shi Q, Okounkova A, Watanabe K, Taniguchi T, Hone J, Dean CR, Li JIA Sperm-mediated 'reverse' gene transfer: a role of reverse transcriptase in the generation of new genetic information. Hum Reprod. 2008 Apr;23(4):735-40. doi: 10.1093/humrep/dem425. Epub 2008 Feb 11. Spadafora C Dog ownership at three months of age is associated with protection against food allergy. Allergy. 2019 Nov;74(11):2212-2219. doi: 10.1111/all.13868. Epub 2019 Jul 8. Marrs T, Logan K, Craven J, Radulovic S, McLean WHAI, Lack G, Flohr C, Perkin MR; EAT Study Team Newborns' cry melody is shaped by their native language. Curr Biol. 2009 Dec 15;19(23):1994-7. doi: 10.1016/j.cub.2009.09.064. Epub 2009 Nov 5. Mampe B, Friederici AD, Christophe A, Wermke K Genome instability triggers intercellular DNA transfer between human cells. Cell. 2026 May 19:S0092-8674(26)00508-8. doi: 10.1016/j.cell.2026.04.041. Maurais EG, Mazzagatti A, Lin YF, Narozna M, Hu Q, Dahiya R, Santiago-Ferrer D, Herlihy CP, Krebs M, Pateraki N, Parcharidou E, Papathanasiou S, Beliveau BJ, Gorbsky GJ, Cortés-Ciriano I, Ly P De novo design of miniproteins targeting GPCRs. Nature. 2026 May 21. doi: 10.1038/s41586-026-10656-8. Muratspahić E, Feldman D, Kim DE, Qu X, Bratovianu AM, Rivera-Sánchez P, Voss JH, Hertz EPT, Jeppesen M, Dimitri F, Sakamoto K, Nallathambi A, Peceli P, Cao J, Cary BP, Belousoff MJ, Keov P, Trinh PNH, Chen Q, Ren Y, Fine J, Mishra S, Dalal A, Sinha S, Banerjee R, Ganguly M, Karuppusamy KV, Sappington I, Schlichthaerle T, Zhang JZ, Pillai A, Coventry B, Mihaljević L, Bauer M, Torres SV, Motmaen A, Lee GR, Tran L, Wang X, Goreshnik I, Vafeados DK, Svendsen JE, Hosseinzadeh P, Lindegaard N, Brandt M, Waltenspühl Y, Deibler K, Deweid L, Bennett A, Schöppe J, Dong T, Yan X, Oostdyk L, Cao W, Anantharaman L, Weisser JJ, Bastlund JF, Bundgaard C, Asuni AA, English JG, Stewart L, Halloran L, Spangler JB, Lieber A, Shukla AK, Sexton PM, Roth BL, Krumm BE, Wootten D, Tate CG, Norn C, Baker D Accelerating scientific discovery with Co-Scientist. Nature. 2026 May 19. doi: 10.1038/s41586-026-10644-y. Gottweis J, Weng WH, Daryin A, Tu T, Sirkovic P, Myaskovsky A, Glowaty G, Weissenberger F, Orlandi A, Popovici D, Palepu A, Rong K, Tanno R, Saab K, Zhang F, Blum J, Carroll A, Kulkarni K, Tomašev N, Zverinski D, Rendulic I, Vedadi E, Hasler F, Rimanic L, Boia M, Budiselic I, Feinstein B, Bellaiche M, Sheffer T, Freyberg J, Ratcliff J, Bertolli O, Chou K, Hassidim A, Gokturk B, Vahdat A, Guan Y, Dhillon V, Vaishnav ED, Lee B, Costa TRD, Penadés JR, Peltz G, Matias Y, Manyika J, Hassabis D, Xu Y, Kohli P, Pawlosky A, Karthikesalingam A, Natarajan V Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer. Cell. 2026 May 19:S0092-8674(26)00505-2. doi: 10.1016/j.cell.2026.04.038. Ho YH, Bregni G, Stazi M, Peinado P, Chen PH, Ballabio C, Boulat V, Vadera S, Guan Y, Liu Z, Alonso de la Vega A, Wang L, Ho CC, Veiga-Fernandes H, Downward J, Hsieh MS, Kopanitsa MV, Kassiotis G, Tsantoulas C, Schappe MS, Margineanu MB, Calado DP, Chiu IM, Swanton C, Chen JS, Li L FERONIA orchestrates plasma membrane nanoclusters for plant thermotolerance. Science. 2026 May 21;392(6800):885-890. doi: 10.1126/science.aeb1752. Epub 2026 May 21. Wang K, Yan H, Guo X, Lin Q, Li J, Peng A, Fu Y, Gong Z, Yang S, Ding Y A multi-agent system for automating scientific discovery. Nature. 2026 May 19. doi: 10.1038/s41586-026-10652-y. Ghareeb AE, Chang B, Mitchener L, Yiu A, Szostkiewicz CJ, Shved D, Gyimesi GJ, Laurent JM, Wright SM, Razzak MT, White AD, Finnemann SC, Hinks MM, Rodriques SG Immunometabolic control of cytokine production by micronutrients in health, aging, and inflammation. Front Immunol. 2026 May 5;17:1781797. doi: 10.3389/fimmu.2026.1781797. eCollection 2026. Ghosh J, Chattopadhyay D Is ADHD in childhood associated with lifetime hoarding symptoms? An epidemiological study. Depress Anxiety. 2013 Aug;30(8):741-8. doi: 10.1002/da.22123. Epub 2013 Apr 19. Fullana MA, Vilagut G, Mataix-Cols D, Adroher ND, Bruffaerts R, Bunting B, de Almeida JM, Florescu S, de Girolamo G, de Graaf R, Haro JM, Kovess V, Alonso J Lonely minds, inflamed guts: metabolic and circulating protein pathways linking social isolation and loneliness to inflammatory bowel disease. Transl Psychiatry. 2026 May 22. doi: 10.1038/s41398-026-04116-0. Zhao J, Ye J, Zhang M, Yu G, Ji H, Zhou S, Jiang F, Xue E, Li K, Yu Z, Yang H, Wu H, Li X Complex interplay of neuronal and hormonal gut-brain responses to essential amino acid deficit. Science. 2026 May 21;392(6800):eadv3355. doi: 10.1126/science.adv3355. Epub 2026 May 21. Kim B, Lee S, Bae H, Kim S, Won JH, Kim D, Jung B, Kanai MI, Yoon SE, Oh Y, Lee WJ, Suh GSB Conflict of Interest Disclosures. A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism. Nat Med. 2026 May 19. doi: 10.1038/s41591-026-04398-3. Martinez-Valbuena I, Emamikhah M, Olszewska DA, Weber SK, Schnell S, Fereshtehnejad SM, Reyes NGD, Sousa M, Di Luca DG, Ta J, Anastassiadis C, Li J, Sasitharan J, Bhakta P, Visanji NP, Fox SH, Mollenhauer B, Tartaglia MC, Kovacs GG, Lang AE A CRISPR activation screen identifies SPART as a pan-orthoflavivirus restriction factor. Cell Host Microbe. 2026 May 19:S1931-3128(26)00174-5. doi: 10.1016/j.chom.2026.04.018. Li Q, Yin Y, Liu Y, Ding X, Nie X, Zhao Z, Zhang R, Ma H, Zhu W, Xiang S, Ouyang H, Yang F, Yang Z, Li Y, Gu J, Yang M, Wang D, Zhu B, Si Y, Chen H, Diamond MS, Cao S, Ye J A deep-learning framework reveals whole-body perturbations at cell level. Nature. 2026 May 20. doi: 10.1038/s41586-026-10535-2. Kaltenecker D, Horvath I, Al-Maskari R, Chen Y, Kolabas ZI, Hoeher L, Todorov M, Minde DP, Kapoor S, Turhan SG, Kuemmerle LB, Steinke H, Wohlgemuth T, Ali M, Kofler F, Morigny P, Geppert J, Jeridi D, Wittmann B, Luo J, Shit S, Cigankova C, Kolenic VM, Gür N, Aydeniz E, Yücecan A, Ertürk M, Simons LHA, Pan C, Piraud M, Rueckert D, Rohm M, Hellal F, Elsner M, Bhatia HS, Bechmann I, Menze BH, Herzig S, Paetzold JC, Diaz MB, Ertürk A Combined ultrasound guided peritendinous hyaluronic acid (500-730 Kda) injection with extracorporeal shock waves therapy vs. extracorporeal shock waves therapy-only in the treatment of shoulder pain due to rotator cuff tendinopathy. A randomized clinical trial. J Sports Med Phys Fitness. 2022 Sep;62(9):1211-1218. doi: 10.23736/S0022-4707.22.13924-1. Epub 2022 Jun 10. Pellegrino R, Brindisino F, Barassi G, Sparvieri E, DI Iorio A, de Sire A, Ruosi C |
||